{"id":42,"date":"2020-04-04T16:44:21","date_gmt":"2020-04-04T16:44:21","guid":{"rendered":"http:\/\/sunpharma-testing.flentas.io\/?page_id=42"},"modified":"2026-01-22T23:28:07","modified_gmt":"2026-01-22T17:58:07","slug":"media","status":"publish","type":"page","link":"https:\/\/dev.sunpharma.com\/he\/media\/","title":{"rendered":"Media"},"content":{"rendered":"

[et_pb_section fb_built=”1″ fullwidth=”on” _builder_version=”4.16″ background_image=”https:\/\/dev.sunpharma.com\/wp-content\/uploads\/2020\/12\/Media_Banner-image.jpg” parallax=”on” da_disable_devices=”off|off|off” saved_tabs=”all” collapsed=”off” global_colors_info=”{}” da_is_popup=”off” da_exit_intent=”off” da_has_close=”on” da_alt_close=”off” da_dark_close=”off” da_not_modal=”on” da_is_singular=”off” da_with_loader=”off” da_has_shadow=”on”][et_pb_fullwidth_header title=”Media” header_fullscreen=”on” button_one_url=”#visionvalues” button_two_url=”#codeofconduct” _builder_version=”4.16″ title_font=”|700|||||||” title_text_color=”#f7941e” title_font_size=”40px” title_line_height=”1.2em” content_font=”||||||||” content_text_color=”#000000″ content_line_height=”1.8em” subhead_font=”||||||||” subhead_text_color=”rgba(0,0,0,0.6)” subhead_font_size=”22px” background_color=”rgba(255,255,255,0.7)” custom_button_one=”on” button_one_text_size=”20px” button_one_text_color=”#ffffff” button_one_bg_color=”#f7941e” button_one_border_width=”0px” button_one_font=”|||on|||||” button_one_use_icon=”off” custom_button_two=”on” button_two_text_size=”20px” button_two_text_color=”rgba(0,0,0,0.7)” button_two_bg_color=”#ffffff” button_two_border_width=”0px” button_two_font=”|||on|||||” button_two_use_icon=”off” button_two_custom_margin=”||||false|false” button_two_custom_margin_tablet=”” button_two_custom_margin_phone=”|||1px|false|false” button_two_custom_margin_last_edited=”on|desktop” button_two_custom_padding=”||||false|false” background_layout=”light” width=”50%” width_tablet=”” width_phone=”100%” width_last_edited=”on|phone” animation_style=”fade” animation_duration=”500ms” animation_delay=”300ms” title_font_tablet=”” title_font_phone=”” title_font_last_edited=”on|phone” content_font_tablet=”” content_font_phone=”” content_font_last_edited=”on|phone” global_colors_info=”{}”]<\/p>\n

Here you will find our latest & archived press releases, stories and our corporate brand guidelines.<\/p>\n

[\/et_pb_fullwidth_header][\/et_pb_section][et_pb_section fb_built=”1″ module_id=”press-releases” _builder_version=”4.16″ background_color=”#f2f2f2″ da_disable_devices=”off|off|off” global_colors_info=”{}” da_is_popup=”off” da_exit_intent=”off” da_has_close=”on” da_alt_close=”off” da_dark_close=”off” da_not_modal=”on” da_is_singular=”off” da_with_loader=”off” da_has_shadow=”on”][et_pb_row _builder_version=”4.16″ width=”90%” max_width=”2560px” custom_padding=”0px||0px||true|false” global_colors_info=”{}”][et_pb_column type=”4_4″ _builder_version=”4.16″ global_colors_info=”{}”][et_pb_text _builder_version=”4.16″ text_font=”|700|||||||” text_font_size=”35px” header_font=”|700|||||||” header_font_size=”35px” header_2_font=”|700|||||||” header_2_text_color=”#f7941e” header_2_font_size=”25px” header_2_line_height=”1.2em” global_colors_info=”{}”]<\/p>\n

Press Releases<\/h2>\n

[\/et_pb_text][et_pb_tabs _builder_version=”4.27.4″ _module_preset=”default” body_line_height=”1.8em” hover_enabled=”0″ global_colors_info=”{}” sticky_enabled=”0″][et_pb_tab title=”2026″ _builder_version=”4.27.4″ _module_preset=”default” hover_enabled=”0″ global_colors_info=”{}” sticky_enabled=”0″]\n\n\n\n\t\n\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t
Press Release<\/th>Date<\/th>\n<\/tr>\n<\/thead>\n
Earnings call for the financial results of the fourth quarter on 22 May 2026
\n<\/a><\/td>		13 May 2026<\/td>\n<\/tr>\n
Investor call to discuss the acquisition of Organon & Co.<\/a><\/td>27 April 2026<\/td>\n<\/tr>\n
Sun Pharma signs Definitive Agreement to Acquire Organon<\/a><\/td>27 April 2026<\/td>\n<\/tr>\n
Sun Pharma Highlights Advances in Alopecia Areata, Psoriasis, and Acne Research at 2026 AAD Annual Meeting<\/a><\/td>27 March 2026<\/td>\n<\/tr>\n
Sun Pharma launches its semaglutide injection under the brand names, Noveltreat and Sematrinity in India Psoriatic Arthritis<\/a><\/td>21 March 2026<\/td>\n<\/tr>\n
Sun Pharma Announces US FDA Acceptance of Supplemental Biologics License (sBLA) Application for ILUMYA\u00ae (tildrakizumab-asmn) for the Treatment of Adults with Active Psoriatic Arthritis <\/a><\/td>March 16, 2026<\/td>\n<\/tr>\n
Sun Pharma Introduces SUNday, Highlighting the Everyday Realities of Skin Cancer Care <\/a><\/td>February 05, 2026<\/td>\n<\/tr>\n
Sun Pharma Comes on Board as Principal Sponsor and Health Partner of Royal Challengers Bengaluru (RCB) for T20 Season 2026 <\/a><\/td>February 04, 2026<\/td>\n<\/tr>\n
Sun Pharma reports Q3FY26 Financial Results<\/a><\/td>January 31, 2026<\/td>\n<\/tr>\n
Sun Pharma receives DCGI approval to manufacture and market generic semaglutide injection in India for chronic weight management<\/a><\/td>January 23, 2026<\/td>\n<\/tr>\n
Earnings call for the financial results of the third quarter on 31 January 2026<\/a><\/td>January 21, 2026<\/td>\n<\/tr>\n
Sun Pharma Announces the Availability of UNLOXCYT\u2122 (cosibelimab-ipdl) for Advanced Cutaneous Squamous Cell Carcinoma (aCSCC)<\/a><\/td>January 15, 2026<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n[\/et_pb_tab][et_pb_tab title=”2025″ _builder_version=”4.16″ _module_preset=”default” global_colors_info=”{}”]\n\n\n\n\t\n\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t
Press Release<\/th>Date<\/th>\n<\/tr>\n<\/thead>\n
Sun Pharma introduces its global innovative drug, Ilumya\u00ae in India for treatment of moderate-to-severe Plaque Psoriasis<\/a><\/td>December 1, 2025<\/td>\n<\/tr>\n
FDA approves label update for UNLOXCYT\u2122 (cosibelimab-ipdl) based on longer-term data that demonstrated improved clinical outcomes in advanced cutaneous squamous cell carcinoma (aCSCC)<\/a><\/td>November 26, 2025<\/td>\n<\/tr>\n
AstraZeneca Pharma India Limited and Sun Pharma partner to help patients living with Hyperkalaemia in India<\/a><\/td>November 17, 2025<\/td>\n<\/tr>\n
Sun Pharma launches \u2018#SeeBeyondSugar\u2019 campaign on World Diabetes Day: A nation-wide initiative to raise awareness about Diabetic Retinopathy<\/a><\/td>November 14, 2025<\/td>\n<\/tr>\n
Sun Pharma Presents Two Posters on Utreglutide at ObesityWeek\u00ae 2025<\/a><\/td>November 12, 2025<\/td>\n<\/tr>\n
Sun Pharma Presents Data from Phase 1b\/2a Study of GL0034 at the American Heart Association 2025 Scientific Sessions<\/a><\/td>November 12, 2025<\/td>\n<\/tr>\n
Philogen provides update on Fibromun clinical study developments<\/a><\/td>November 12, 2025<\/td>\n<\/tr>\n
Sun Pharma reports Q2FY26 Financial Results<\/a><\/td>November 05, 2025<\/td>\n<\/tr>\n
Earnings call for the financial results of the second quarter on 05 November 2025<\/a><\/td>October 15, 2025<\/td>\n<\/tr>\n
Sun Pharma reports Q1FY26 Financial Results<\/a><\/td>July 31, 2025<\/td>\n<\/tr>\n
Sun Pharma\u2019s Phase 3 Clinical Studies Evaluating Tildrakizumab 100 mg (ILUMYA) in Active Psoriatic Arthritis Meet their Primary Endpoint<\/a><\/td>July 21, 2025<\/td>\n<\/tr>\n
Sun Pharma to announce first-quarter results on July 31, 2025<\/a><\/td>July 15, 2025<\/td>\n<\/tr>\n
Sun Pharma Announces Launch of LEQSELVI\u2122 (deuruxolitinib) in the United States for the Treatment of Severe Alopecia Areata<\/a><\/td>July 14, 2025<\/td>\n<\/tr>\n
Sun Pharma announces settlement with Incyte Corporation in litigation relating to LEQSELVI\u2122<\/a><\/td>July 14, 2025<\/td>\n<\/tr>\n
Philogen Provides Update on Marketing Authorization Application for Nidlegy\u2122 in the European Union<\/a><\/td>June 24, 2025<\/td>\n<\/tr>\n
Sun Pharma Announces Top-Line Results from the Phase 2 Clinical Trials Evaluating SCD-044 for Moderate to Severe Psoriasis and Atopic Dermatitis<\/a><\/td>June 3, 2025<\/td>\n<\/tr>\n
Sun Pharma appoints Kirti Ganorkar as the Managing Director; Dilip Shanghvi to continue as the Executive Chairman of the Board<\/a><\/td>June 13, 2025<\/td>\n<\/tr>\n
Sun Pharma announces the completion of its acquisition of Checkpoint Therapeutics, Inc.<\/a><\/td>May 30, 2025<\/td>\n<\/tr>\n
Sun Pharma reports Q4 and full year results for FY25<\/a><\/td>May 22, 2025<\/td>\n<\/tr>\n
Sun Pharma to announce fourth-quarter results on May 22, 2025<\/a><\/td>May 12, 2025<\/td>\n<\/tr>\n
Sun Pharma Announces FDA Approval of Next Generation BLU-U\u00ae Blue Light Photodynamic Therapy Illuminator for Actinic Keratosis<\/a><\/td>May 16, 2025<\/td>\n<\/tr>\n
Sun Pharma Launches Corporate Brand Campaign in India
\n<\/a><\/td>		May 8, 2025<\/td>\n<\/tr>\n
Sun Pharma and Moebius Medical Announce Dual Publications on MM-II\u2019s Phase 2b Clinical Trial Results and Mechanism of Action in Osteoarthritis and Cartilage<\/a><\/td>April 24, 2025<\/td>\n<\/tr>\n
Sun Pharma introduces a novel class of drug, Fexuclue\u00ae(Fexuprazan) in India for treatment of Erosive Esophagitis<\/a><\/td>April 07, 2025<\/td>\n<\/tr>\n
Music Icon Art Garfunkel Opens Up About His Experience with Psoriasis in Partnership with Sun Pharma<\/a><\/td>April 04, 2025<\/td>\n<\/tr>\n
Sun Pharma to Acquire Checkpoint Therapeutics<\/a><\/td>March 10, 2025<\/td>\n<\/tr>\n
ILUMYA\u00ae Found Effective for Treatment of Plaque Psoriasis Affecting Nails in Study Presented at 2025 AAD Conference<\/a><\/td>March 7, 2025<\/td>\n<\/tr>\n
Sun Pharma Amongst Top 5% Of Global Pharmaceutical Companies In S&P Global Sustainability Yearbook 2025<\/a><\/td>February 17, 2025<\/td>\n<\/tr>\n
Philogen Completes Patient Enrollment of the Phase III FIBROSARC Trial in Soft Tissue Sarcoma<\/a><\/td>February 04, 2025<\/td>\n<\/tr>\n
Sun Pharma reports Q3 FY25 results<\/a><\/td>January 31, 2025<\/td>\n<\/tr>\n
Sun Pharma to announce third-quarter results on January 31, 2025
\n <\/a><\/td>		January 31, 2025<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n[\/et_pb_tab][et_pb_tab title=”2024″ _builder_version=”4.16″ _module_preset=”default” global_colors_info=”{}”]<\/p>\n\n\n\n\n\t\n\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t
Press Release<\/th>Date<\/th>\n<\/tr>\n<\/thead>\n
Sun Pharma reports Q2FY25 results<\/a><\/td>Oct 28, 2024<\/td>\n<\/tr>\n
Sun Pharma Presents LEQSELVI at the 2024 Fall Clinical Dermatology Conference<\/a><\/td>Oct 25, 2024<\/td>\n<\/tr>\n
WINLEVI poster presentations at 2024 Fall Clinical Dermatology Conference<\/a><\/td>Oct 25, 2024<\/td>\n<\/tr>\n
Sun Pharma to announce Second quarter results on October 28, 2024<\/a><\/td>Oct 1, 2024<\/td>\n<\/tr>\n
Sun Pharma and Philogen enter into a global Exclusive Commercialization, License, and Supply Agreement for Commercializing the specialty product FIBROMUN<\/a><\/td>Oct 1, 2024<\/td>\n<\/tr>\n
Sun Pharma Presents New Clinical Efficacy and Safety Data in Severe Dermatological Conditions at the 2024 European Academy of Dermatology and Venereology (EADV) Congress<\/a><\/td>Sept 26, 2024<\/td>\n<\/tr>\n
Sun Pharma and Moebius Medical Announce Fast Track Designation Granted for MM-II for the Treatment of Osteoarthritis Knee Pain<\/a><\/td>Sept 06, 2024<\/td>\n<\/tr>\n
Sun Pharma introduces a novel treatment, STARIZO (Tedizolid Phosphate) in India for acute bacterial skin and skin structure infections<\/a><\/td>August 23, 2024<\/td>\n<\/tr>\n
Sun Pharma reports Q1 FY25 Financial Press Release<\/a><\/td>August 01, 2024<\/td>\n<\/tr>\n
U.S. FDA Approves LEQSELVI\u2122 (deuruxolitinib), an Oral JAK Inhibitor for the Treatment of Severe Alopecia Areata<\/a><\/td>July 26, 2024<\/td>\n<\/tr>\n
Sun Pharma to announce first quarter results on August 01, 2024<\/a><\/td>July 16, 2024<\/td>\n<\/tr>\n
Validation of Nidlegy\u2122 Marketing Authorization Application Submission by EMA<\/a><\/td>July 04, 2024<\/td>\n<\/tr>\n
Sun Pharma Launches #SecondBirthDate 2.0 Initiative with Sushmita Sen on National Doctors\u2019 Day: Celebrating Real-life Heroes<\/a><\/td>July 01, 2024<\/td>\n<\/tr>\n
Sun Pharma Completes Taro Merger<\/a><\/td>June 24, 2024<\/td>\n<\/tr>\n
Sun Pharma\u2019s GL0034 (Utreglutide) Demonstrates Significant Weight Loss, Gluco-metabolic and Lipid Lowering Efficacy in Individuals with Obesity in Oral Presentation at the American Diabetes Association 84th Scientific Sessions<\/a><\/td>June 22, 2024<\/td>\n<\/tr>\n
Sun Pharma signs non-exclusive patent licensing agreement with Takeda for introducing Novel Gastrointestinal Drug, Voltapraz (Vonoprazan) in India<\/a><\/td>June 21, 2024<\/td>\n<\/tr>\n
Oral Presentation at EULAR 2024 of Data from Global Phase 2b Clinical Trial Demonstrates Durability of Pain Relief After a Single Injection of MM-II in Patients with Painful Knee Osteoarthritis (OA)<\/a><\/td>June 14, 2024<\/td>\n<\/tr>\n
Press Release Nidlegy\u2122 Marketing Authorization Application Submitted to EMA<\/a><\/td>June 04, 2024<\/td>\n<\/tr>\n
Press Release Results of the Phase III PIVOTAL trial of Nidlegy in melanoma to be presented at ASCO 2024<\/a><\/td>May 31, 2024<\/td>\n<\/tr>\n
Taro Shareholders Approve Merger with Sun Pharma<\/a><\/td>May 23, 2024<\/td>\n<\/tr>\n
Sun Pharma reports Q4 and full year FY24 Financial Press Release<\/a><\/td>May 22, 2024<\/td>\n<\/tr>\n
Sun Pharma to announce fourth quarter results on May 22, 2024<\/a><\/td>May 15, 2024<\/td>\n<\/tr>\n
Sun Pharmaceuticals announces approval of Winlevi\u00ae<\/sup> in Australia<\/a><\/td>March 19, 2024<\/td>\n<\/tr>\n
Sun Pharma included in S&P Global Sustainability Yearbook 2024<\/a><\/td>February 12, 2024<\/td>\n<\/tr>\n
Sun Pharma reports Q3FY24 results<\/a><\/td>January 31, 2024<\/td>\n<\/tr>\n
Taro Announces Merger Agreement with Sun Pharma<\/a><\/td>January 18, 2024<\/td>\n<\/tr>\n
Sun Pharma and Bayer sign marketing and distribution agreement for second brand of Finerenone in India
\n<\/a><\/td>		January 17, 2024<\/td>\n<\/tr>\n
Sun Pharma to announce third quarter results on January 31, 2024<\/a><\/td>January 16, 2024<\/td>\n<\/tr>\n
<\/td><\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n\n

[\/et_pb_tab][et_pb_tab title=”2023″ _builder_version=”4.16″ _module_preset=”default” global_colors_info=”{}”]\n\n\n\n\t\n\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t
Press Release<\/th>Date<\/th>\n<\/tr>\n<\/thead>\n
Q2 FY24 Financial Press Release<\/a><\/td>November 1, 2023<\/td>\n<\/tr>\n
Sun Pharma and Zydus sign licensing agreement for co-marketing of Desidustat in India<\/a><\/td>October 30, 2023<\/td>\n<\/tr>\n
Sun Pharma to announce second quarter results on November 01, 2023<\/a><\/td>October 17, 2023<\/td>\n<\/tr>\n
Nidlegy\u2122 Phase III PIVOTAL trial meets the study\u2019s primary objective demonstrating statistically significant and clinically meaningful improvement in Recurrence-Free Survival for patients with locally advanced fully resectable melanoma<\/a><\/td>October 16, 2023<\/td>\n<\/tr>\n
CEQUA\u00ae (cyclosporine ophthalmic solution) 0.09% Phase 4 Data Showed Sustained Improvement in Dry Eye Disease Signs and Symptoms in Patients Switched From Restasis\u00ae (cyclosporine ophthalmic emulsion) 0.05%<\/a><\/td>October 12, 2023<\/td>\n<\/tr>\n
Sun Pharma Announces US FDA Filing Acceptance of New Drug Application For Deuruxolitinib<\/a><\/td>October 6, 2023<\/td>\n<\/tr>\n
Sun Pharma Canada Launches PR <\/sup>WINLEVI\u00ae (clascoterone cream 1% w\/w), a Novel Topical Treatment for Acne<\/a><\/td>September 27, 2023<\/td>\n<\/tr>\n
Sun Pharma and Pharmazz Inc. enter into licensing agreement for introducing Tyvalzi\u2122 (Sovateltide) in India<\/a><\/td>September 14, 2023<\/td>\n<\/tr>\n
Sun Pharma to announce first quarter results on August 03, 2023<\/a><\/td>July 17, 2023<\/td>\n<\/tr>\n
Sun Pharma launches nationwide initiative, #SecondBirthDate on National Doctor\u2019s Day<\/a><\/td>July 1, 2023<\/td>\n<\/tr>\n
ADA GL0034 Data Release<\/a><\/td>June 24, 2023<\/td>\n<\/tr>\n
Sun Pharma Announces Health Canada Approval of PRWINLEVI\u00ae (clascoterone cream 1%) for Topical Treatment of Acne<\/a><\/td>June 19, 2023<\/td>\n<\/tr>\n
Sun Pharma Announces China NMPA Approval For ILUMETRI (Tildrakizumab Injection) For Treatment Of Adults with Moderate-To-Severe Plaque Psoriasis<\/a><\/td>May 30, 2023<\/td>\n<\/tr>\n
Sun Pharma and Philogen enter into an Exclusive Distribution, License, and Supply Agreement for Commercializing specialty product, NIDLEGY\u2122 in Europe, Australia and New Zealand<\/a><\/td>May 30, 2023<\/td>\n<\/tr>\n
Q4 FY23 Financial Press Release<\/a><\/td>May 26, 2023<\/td>\n<\/tr>\n
Sun Pharma to announce fourth quarter results on May 26, 2023<\/a><\/td>May 26, 2023<\/td>\n<\/tr>\n
Sun Pharma launches CEQUA, a novel therapy for Dry Eye Disease in India<\/a><\/td>April 25, 2023<\/td>\n<\/tr>\n
Osteoarthritis Candidate MM-II Showed Durable Pain Relief in Global Phase 2b Study<\/a><\/td>March 22, 2023<\/td>\n<\/tr>\n
Late-Breaking Phase 3 Data at AAD 2023 Show Oral Investigational Medicine Deuruxolitinib Significantly Improved Scalp Hair Regrowth in Alopecia Areata<\/a><\/td>March 18, 2023<\/td>\n<\/tr>\n
Sun Pharma completes acquisition of Concert Pharmaceuticals<\/a><\/td>March 06, 2023<\/td>\n<\/tr>\n
Sun Pharma Announces US FDA Approval for Generic Lenalidomide Capsules<\/a><\/td>February 10, 2023<\/td>\n<\/tr>\n
Q3 FY23 Financial Press Release<\/a><\/td>January 31, 2023<\/td>\n<\/tr>\n
Sun Pharma acquires Disperzyme\u00ae and Phlogam\u00ae brands to strengthen its anti-inflammatory portfolio<\/a><\/td>January 30, 2023<\/td>\n<\/tr>\n
Sun Pharma Launches SEZABY\u2122 (phenobarbital sodium) in the U.S. for Treatment of Neonatal Seizures<\/a><\/td>January 25, 2023<\/td>\n<\/tr>\n
Sun Pharma to Acquire Concert Pharmaceuticals Inc<\/a<\/td>January 19, 2023<\/td>\n<\/tr>\n
Sun Pharma to announce third quarter results on January 31, 2023<\/a><\/td>January 17, 2023<\/td>\n<\/tr>\n
Sun Pharma launches Palbociclib, a novel targeted therapy for advanced breast cancer with a unique Patient Assistance Program<\/a><\/td>January 11, 2023<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n[\/et_pb_tab][et_pb_tab title=”2022″ _builder_version=”4.16″ _module_preset=”default” global_colors_info=”{}”]<\/p>\n\n\n\n\n\t\n\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t
Press Release <\/th>Date<\/th>\n<\/tr>\n<\/thead>\n
Sun Pharma is Great Place To Work\u00ae Certified\u2122 in India<\/a><\/td>December 21, 2022<\/td>\n<\/tr>\n
SEZABY\u2122 (phenobarbital sodium powder for injection) approved by US FDA for the treatment of neonatal seizures<\/a><\/td>November 18, 2022<\/td>\n<\/tr>\n
Sun Pharma and SPARC enter into a license agreement for commercialization of phenobarbital for injection in the US<\/a><\/td>November 09, 2022<\/td>\n<\/tr>\n
Q2 FY23 Financial Press Release<\/a><\/td>November 01, 2022<\/td>\n<\/tr>\n
\u201cApni Body Ki Suno\u201d says the latest campaign of Sun Pharma\u2019s Revital H<\/a><\/td>October 14, 2022<\/td>\n<\/tr>\n
Sun Pharma to announce second quarter results on November 01, 2022<\/a>
\n<\/td>		October 11, 2022<\/td>\n<\/tr>\n
Sun Pharma Chairman, Israel Makov to retire on completion of term<\/a><\/td>August 03, 2022<\/td>\n<\/tr>\n
Sun Pharma and Cosmo Announce Territory Expansion of License and Supply Agreements for WINLEVI\u00ae to include Japan, Australia, New Zealand, Brazil, Mexico and Russia<\/a><\/td>July 26, 2022<\/td>\n<\/tr>\n
Sun Pharma to announce first quarter results on July 29, 2022<\/a><\/td>July 13, 2022<\/td>\n<\/tr>\n
Q4 FY22 Financial Press Release<\/a><\/td>May 30, 2022<\/td>\n<\/tr>\n
Sun Pharma Acquires Uractiv\u2122 Portfolio from Fiterman Pharma in Romania<\/a><\/td>May 27, 2022<\/td>\n<\/tr>\n
Sun Pharma to launch Brillo\u00ae, a first-in-class oral lipid-lowering drug in India<\/a><\/td>May 18, 2022<\/td>\n<\/tr>\n
Sun Pharma to announce fourth quarter results on May 30, 2022<\/a><\/td>May 16, 2022<\/td>\n<\/tr>\n
Sun Pharma Announces US FDA Approval for Generic Mesalamine Extended Release Capsules<\/a><\/td>May 12, 2022<\/td>\n<\/tr>\n
Sun Pharma to introduce its version of Vortioxetine in India under an exclusive patent license from Lundbeck<\/a><\/td>March 30, 2022<\/td>\n<\/tr>\n
Intimation under Regulation 30- 29th March, 2022<\/a><\/td>March 29, 2022<\/td>\n<\/tr>\n
Sun Pharma Presents Phase 3 Data for WINLEVI\u00ae (clascoterone) cream 1% for the Topical Treatment of Acne Vulgaris at the AAD Annual Meeting<\/a><\/td>March 25, 2022<\/td>\n<\/tr>\n
Q3 FY22 Financial Press Release<\/a><\/td>January 31, 2022<\/td>\n<\/tr>\n
Sun Pharma launches CEQUA\u2122 (cyclosporine ophthalmic solution 0.09% w\/v), the first dry eye treatment with nanomicellar (NCELL\u2122) technology*, in Canada<\/a><\/td>January 27, 2022<\/td>\n<\/tr>\n
Sun Pharma to announce third quarter results on January 31, 2022<\/a><\/td>January 18, 2022<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n\n

[\/et_pb_tab][et_pb_tab title=”2021″ _builder_version=”4.16″ _module_preset=”default” global_colors_info=”{}”]<\/p>\n\n\n\n\n\t\n\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t
Press Release<\/th>Date<\/th>\n<\/tr>\n<\/thead>\n
Sun Pharma receives DCGI approval for Molxvir\u00ae (Molnupiravir) in India<\/a><\/td>December 28, 2021<\/td>\n<\/tr>\n
Sun Pharma Announces US FDA Approval for Generic Amphotericin B Liposome Injection<\/a><\/td>December 15, 2021<\/td>\n<\/tr>\n
Sun Pharma geared to introduce Molnupiravir, licensed from MSD and Ridgeback, under the brand name Molxvir\u00ae in India<\/a><\/td>November 11, 2021<\/td>\n<\/tr>\n
Q2 FY22 Financial Press Release<\/a><\/td>November 2, 2021<\/td>\n<\/tr>\n
Sun Pharma Announces Availability of WINLEVI\u00ae (clascoterone) cream 1% in the U.S. for Topical Treatment of Acne Vulgaris<\/a><\/td>November 1, 2021<\/td>\n<\/tr>\n
Sun Pharma\u2019s ILUMYA\u2122 (tildrakizumab injection) now available to help Canadians living with moderate-to-severe plaque psoriasis<\/a><\/td>October 28, 2021<\/td>\n<\/tr>\n
Sun Pharma to announce second quarter results on November 02, 2021<\/a><\/td>October 19, 2021<\/td>\n<\/tr>\n
Sun Pharma launches Chericof\u00ae 12 in India, a novel formulation that provides relief from cough for up to 12 hours<\/a><\/td>September 28, 2021<\/td>\n<\/tr>\n
Sun Pharma forays into Nutrition Bar segment with the launch of Revital NXT<\/a><\/td>September 08, 2021<\/td>\n<\/tr>\n
Sun Pharma and Cassiopea announce the expiry of the HSR Act process and the successful consummation of their Winlevi\u00ae (clascoterone cream 1%) agreement<\/a><\/td>August 31, 2021<\/td>\n<\/tr>\n
Q1 FY22 Financial Press Release<\/a><\/td>July 30, 2021<\/td>\n<\/tr>\n
Sun Pharma and Cassiopea SpA Announce Signing of License and Supply Agreements for Winlevi\u00ae (clascoterone cream 1%) in US and Canada<\/a><\/td>July 26, 2021<\/td>\n<\/tr>\n
Sun Pharma to announce first quarter results on July 30, 2021<\/a><\/td>July 16, 2021<\/td>\n<\/tr>\n
Sun Pharma launches \u2018Sunkalp\u2019 on the occasion of National Doctors\u2019 Day<\/a><\/td>July 01, 2021<\/td>\n<\/tr>\n
Press Release Pharma Majors Collaborate for Clinical Trial of Anti Viral Drug Molnupiravir for COVID-19<\/a><\/td>June 29, 2021<\/td>\n<\/tr>\n
Press Release Settlement of Patent Litigation for Generic Revlimid in US<\/a><\/td>June 22, 2021<\/td>\n<\/tr>\n
Sun Pharma and Ferring Pharmaceuticals enter into licensing agreement for introducing CARITEC\u00ae in India<\/a><\/td>June 02, 2021<\/td>\n<\/tr>\n
Q4 FY21 Financial Press Release<\/a><\/td>May 27, 2021<\/td>\n<\/tr>\n
Sun Pharma Q4 FY21 financial result on May 27, 2021<\/a><\/td>May 12, 2021<\/td>\n<\/tr>\n
Sun Pharma signs voluntary licensing agreement with Eli Lilly for expanding access to Baricitinib to help alleviate the burden of Covid-19 in India<\/a><\/td>May 10, 2021<\/td>\n<\/tr>\n
Sun Pharma Launches Website for its Long Term Care Portfolio in the US<\/a><\/td>February 25, 2021<\/td>\n<\/tr>\n
Sun Pharma to introduce complete range of Brivaracetam at an affordable price for epilepsy treatment in India<\/a><\/td>February 23, 2021<\/td>\n<\/tr>\n
SPIL Q3FY21 Financials Results<\/a><\/td>January 29, 2021<\/td>\n<\/tr>\n
Sun Pharma\u2019s financials for Q3 and nine month period ending December 31, 2020<\/a><\/td>January 29, 2021<\/td>\n<\/tr>\n
Sun Pharma to announce third quarter results on January 29, 2021<\/a><\/td>January 04, 2021<\/td>\n<\/tr>\n
Sun Pharma announces initiation of Phase 2 Clinical Trial of SCD-044 in Patients with Moderate to Severe Plaque Psoriasis<\/a><\/td>January 04, 2021<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n\n

[\/et_pb_tab][et_pb_tab title=”2020″ _builder_version=”4.16″ _module_preset=”default” global_colors_info=”{}”]<\/p>\n\n\n\n\n\t\n\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t
Press Release<\/th>Date<\/th>\n<\/tr>\n<\/thead>\n
FY21 Q2 Financial Press Release<\/a><\/td>November 03, 2020<\/td>\n<\/tr>\n
FY21 Q2 Financial Results<\/a><\/td>November 03, 2020<\/td>\n<\/tr>\n
Sun Pharma Announces 5-Year Sustained Efficacy and Safety Results for ILUMYA\u00ae in Patients with Moderate-to-Severe Plaque Psoriasis<\/a><\/td>October 31, 2020<\/td>\n<\/tr>\n
Sun Pharma to announce Second quarter results on November 03, 2020<\/a><\/td>October 22, 2020<\/td>\n<\/tr>\n
Press Release Sun Pharma announces the launch of ILUMYA for treatment of plaque psoriasis in Japan<\/a><\/td>September 23, 2020<\/td>\n<\/tr>\n
FY21 Q1 Financial Result - Transcript<\/a><\/td>August 26, 2020<\/td>\n<\/tr>\n
Sun Pharma launches FluGuard\u00ae (Favipiravir) in India at Rs. 35 per tablet<\/a><\/td>August 04, 2020<\/td>\n<\/tr>\n
FY21 Q1 Financial Press Release<\/a><\/td>July 31, 2020<\/td>\n<\/tr>\n
FY21 Q1 Financial Results<\/a><\/td>July 31, 2020<\/td>\n<\/tr>\n
Sun Pharma launches \u2018Thank you Doctor\u2019 campaign<\/a><\/td>July 09, 2020<\/td>\n<\/tr>\n
FY20 Q4 Financial Result - Transcript<\/a><\/td>July 06, 2020<\/td>\n<\/tr>\n
Sun Pharma announces Japan MHLW approval of ILUMYA for the treatment of Plaque Psoriasis<\/a><\/td>June 29, 2020<\/td>\n<\/tr>\n
Sun Pharma Announces Pre-Clinical Data on GL0034<\/a><\/td>June 24, 2020<\/td>\n<\/tr>\n
Sun Pharma and Hikma enter into exclusive licensing agreement for ILUMYA\u2122 for Middle East & North Africa regions<\/a><\/td>June 15, 2020<\/td>\n<\/tr>\n
Sun Pharma Announces Long-term Insights into the Clinical Use of ILUMYA TM<\/a><\/td>June 13, 2020<\/td>\n<\/tr>\n
Sun Pharma Presents ODOMZO\u00ae and LEVULAN\u00ae KERASTICK\u00ae + BLU-U\u00ae Data, Offering Clinical Insights for Treating People with or at Risk of Skin Cancer<\/a><\/td>June 13, 2020<\/td>\n<\/tr>\n
Sun Pharma initiates Phase II clinical trial on AQCH, a phytopharmaceutical drug, as potential treatment for COVID-19 patients<\/a><\/td>June 05, 2020<\/td>\n<\/tr>\n
Sun Pharma receives approval from DCGI to initiate clinical trial with Nafamostat in Covid 19 patients<\/a><\/td>May 29, 2020<\/td>\n<\/tr>\n
Sun Pharma and SPARC enter into a worldwide license agreement for SCD 044<\/a><\/td>May 28, 2020<\/td>\n<\/tr>\n
Sun Pharma Q4FY20 Financial Results<\/a><\/td>May 27, 2020<\/td>\n<\/tr>\n
FY20 Q4 Financial Press Release<\/a><\/td>May 27, 2020<\/td>\n<\/tr>\n
FY20 Q4 Financial Results<\/a><\/td>May 27, 2020<\/td>\n<\/tr>\n
Sun Pharma to announce fourth quarter results on May 27, 2020<\/a><\/td>May 19, 2020<\/td>\n<\/tr>\n
FY20 Q3 Financial Result - Transcript<\/a><\/td>April 09, 2020<\/td>\n<\/tr>\n
Sun Pharma Commits Donation of Medicines and Hand Sanitizers to Support India\u2019s COVID-19 Pandemic Response<\/a><\/td>March 27, 2020<\/td>\n<\/tr>\n
SPII Donates 2.5 Million Hydroxychloroquine Sulfate Tablets in the U.S. For Potential COVID-19 Treatment<\/a><\/td>March 27, 2020<\/td>\n<\/tr>\n
FY20 Q3 Financial Results<\/a><\/td>February 06, 2020<\/td>\n<\/tr>\n
FY20 Q3 Financial Press Release<\/a><\/td>February 06, 2020<\/td>\n<\/tr>\n
Sun Pharma Introduces ABSORICA LD\u2122 Capsules for Management of Severe Recalcitrant Nodular Acne in the U.S.<\/a><\/td>February 04, 2020<\/td>\n<\/tr>\n
Sun Pharma to announce third quarter results on 06 February 2020<\/a><\/td>January 20, 2020<\/td>\n<\/tr>\n
Sun Pharma and Rockwell Medical enter into licensing agreement for Triferic in India<\/a><\/td>January 15, 2020<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n\n

[\/et_pb_tab][et_pb_tab title=”2019″ _builder_version=”4.16″ _module_preset=”default” global_colors_info=”{}”]<\/p>\n\n\n\n\n\t\n\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t
Press Release<\/th>Date<\/th>\n<\/tr>\n<\/thead>\n
FY20 Q2 Financial Result - Transcript<\/a><\/td>December 10, 2019<\/td>\n<\/tr>\n
FY20 Q2 Financial Results<\/a><\/td>November 07, 2019<\/td>\n<\/tr>\n
FY20 Q2 Financial Press Release<\/a><\/td>November 07, 2019<\/td>\n<\/tr>\n
Sun Pharma and AstraZeneca enter into License Agreement for Novel Oncology products in China<\/a><\/td>November 06, 2019<\/td>\n<\/tr>\n
Sun Pharma to announce second quarter results on 07 November 2019<\/a><\/td>October 24, 2019<\/td>\n<\/tr>\n
Sun Pharma Launches Drizalma Sprinkle in the US<\/a><\/td>October 16, 2019<\/td>\n<\/tr>\n
Sun Pharma Launches CEQUA for the Treatment of Dry Eye Disease in the US<\/a><\/td>October 14, 2019<\/td>\n<\/tr>\n
Malaria Elimination Programme Receives Mahatma Award for Social Good<\/a><\/td>October 10, 2019<\/td>\n<\/tr>\n
Sun Pharma Presents Long-term Study Results that Show Significant Skin Clearance with ILUMYA<\/a><\/td>October 09, 2019<\/td>\n<\/tr>\n
FY20 Q1 Financial Result - Transcript<\/a><\/td>October 03, 2019<\/td>\n<\/tr>\n
Sun Pharma and China Medical System Holdings Enter into Licensing Agreement for Generic Products in Mainland China<\/a><\/td>August 16, 2019<\/td>\n<\/tr>\n
Sun Pharma and China Medical System Holdings Enter into Licensing Agreement for Generic Products in Mainland ChinaSun Pharma Announces Licensing Agreement With CSIR-IICT<\/a><\/td>August 14, 2019<\/td>\n<\/tr>\n
FY20 Q1 Financial Results<\/a><\/td>August 13, 2019<\/td>\n<\/tr>\n
FY20 Q1 Financial Press Release<\/a><\/td>August 13, 2019<\/td>\n<\/tr>\n
Sun Pharma to announce first quarter results on August 13, 2019<\/a><\/td>August 05, 2019<\/td>\n<\/tr>\n
Sun Pharma Announces Regulatory Filing of Tildrakizumab in Japan<\/a><\/td>August 01, 2019<\/td>\n<\/tr>\n
Sun Pharma Launches Ezallor Sprinkle (Rosuvastatin) in the U.S. for People Who Have Difficulty Swallowing<\/a><\/td>July 15, 2019<\/td>\n<\/tr>\n
Sun Pharma and China Medical System Holdings enter into a License Agreement for Tildrakizumab in Greater China<\/a><\/td>June 27, 2019<\/td>\n<\/tr>\n
Sun Pharma and China Medical System Holdings enter into a License Agreement for Cyclosporine A eye drops in Greater China<\/a><\/td>June 27, 2019<\/td>\n<\/tr>\n
Late Breaking Phase 2 Data Showing Potential of ILUMYA for Psoriatic Arthritis<\/a><\/td>June 14, 2019<\/td>\n<\/tr>\n
FY19 Q4 Financial Results<\/a><\/td>May 28, 2019<\/td>\n<\/tr>\n
FY19 Q4 Financial Press Release<\/a><\/td>May 28, 2019<\/td>\n<\/tr>\n
Sun Pharma to announce fourth quarter results on May 28, 2019<\/a><\/td>May 14, 2019<\/td>\n<\/tr>\n
Sun Pharma Launches Ready-to-Infuse INFUGEM in the U.S.<\/a><\/td>April 08, 2019<\/td>\n<\/tr>\n
FY19 Q3 Financial Result - Transcript<\/a><\/td>March 08, 2019<\/td>\n<\/tr>\n
ILUMYA 3 Year Data Demonstrates Sustained Skin Clearance in Patients with Moderate to Severe Plaque Psoriasis<\/a><\/td>March 01, 2019<\/td>\n<\/tr>\n
FY19 Q3 Financial Press Release<\/a><\/td>February 12, 2019<\/td>\n<\/tr>\n
Sun Pharma Q3 FY19 financial result on 12 February 2019<\/a><\/td>January 28, 2019<\/td>\n<\/tr>\n
Press Release Sun Pharma Investor Update<\/a><\/td>January 22, 2019<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n\n

[\/et_pb_tab][et_pb_tab title=”2018″ _builder_version=”4.16″ _module_preset=”default” global_colors_info=”{}”]<\/p>\n\n\n\n\n\t\n\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t
Press Release<\/th>Date<\/th>\n<\/tr>\n<\/thead>\n
Investor Update Call Transcript<\/a><\/td>December 27, 2018<\/td>\n<\/tr>\n
DUSA Pharmaceuticals, Inc. Awarded Preliminary Injunctive Relief Prohibiting Biofrontera From Using Its Trade Secrets<\/a><\/td>December 26, 2018<\/td>\n<\/tr>\n
Clarification on recent media reports<\/a><\/td>December 03, 2018<\/td>\n<\/tr>\n
Sun Pharma Announces US FDA Approval For Generic Ganirelix Acetate Injection<\/a><\/td>December 03, 2018<\/td>\n<\/tr>\n
Sun Pharma to hold an Investor Update Call on 03 December 2018<\/a><\/td>December 03, 2018<\/td>\n<\/tr>\n
Sun Pharma to acquire Pola Pharma in Japan<\/a><\/td>November 26, 2018<\/td>\n<\/tr>\n
FY19 Q2 Financial Result - Transcript<\/a><\/td>November 20, 2018<\/td>\n<\/tr>\n
FY19 Q2 Financial Press Release<\/a><\/td>November 13, 2018<\/td>\n<\/tr>\n
Sun Pharma Announces the Availability of ILUMYA in the United States<\/a><\/td>October 23, 2018<\/td>\n<\/tr>\n
Sun Pharma to announce second quarter results on 13 November 2018<\/a><\/td>October 23, 2018<\/td>\n<\/tr>\n
Sun Pharma announces Australian TGA approval of ILUMYA<\/a><\/td>September 21, 2018<\/td>\n<\/tr>\n
Sun Pharma Announces Receipt of European Commission Approval For ILUMETRI<\/a><\/td>September 18, 2018<\/td>\n<\/tr>\n
Sun Pharma and SPARC Announce US FDA Approval of XELPROS<\/a><\/td>September 14, 2018<\/td>\n<\/tr>\n
Clarification to Stock Exchanges on Mohali facility<\/a><\/td>September 11, 2018<\/td>\n<\/tr>\n
Clarification to Stock Exchanges on news regarding Halol facility<\/a><\/td>September 07, 2018<\/td>\n<\/tr>\n
FY19 Q1 Financial Result - Transcript<\/a><\/td>September 04, 2018<\/td>\n<\/tr>\n
Sun Pharma launches Volini Maxx, India\u2019s Strongest Pain Relief Spray<\/a><\/td>August 29, 2018<\/td>\n<\/tr>\n
Sun Pharma Announces USFDA Approval of CEQUA to Treat Dry Eye Disease<\/a><\/td>August 16, 2018<\/td>\n<\/tr>\n
FY19 Q1 Financial Press Release<\/a><\/td>August 14, 2018<\/td>\n<\/tr>\n
Sun Pharma Launches Novel Drug Kapspargo Sprinkle\u2122 in USA<\/a><\/td>August 06, 2018<\/td>\n<\/tr>\n
Sun Pharma to announce first quarter results on 14 August 2018<\/a><\/td>July 27, 2018<\/td>\n<\/tr>\n
Sun Pharma Announces Launch of Generic Glumetza\u00ae Tablets in US<\/a><\/td>July 25, 2018<\/td>\n<\/tr>\n
Sun Pharma Announces USFDA Approval of INFUGEM Injection<\/a><\/td>July 18, 2018<\/td>\n<\/tr>\n
DUSA Pharmaceuticals, Inc. files lawsuit against Biofrontera Inc.<\/a><\/td>July 11, 2018<\/td>\n<\/tr>\n
Sun Pharma signs Akshay Kumar as Revital H Brand Ambassador<\/a><\/td>July 09, 2018<\/td>\n<\/tr>\n
Sun Pharma receives EIR for Halol facility<\/a><\/td>June 12, 2018<\/td>\n<\/tr>\n
Clarification on news regarding Halol<\/a><\/td>June 08, 2018<\/td>\n<\/tr>\n
FY18 Q4 Financial Result - Transcript<\/a><\/td>June 08, 2018<\/td>\n<\/tr>\n
FY18 Q4 Financial Press Release<\/a><\/td>May 25, 2018<\/td>\n<\/tr>\n
Sun Pharma Announces USFDA Approval of YONSA<\/a><\/td>May 23, 2018<\/td>\n<\/tr>\n
Sun Pharma Announces US Launch of Authorized Generic for Welchol Tablets<\/a><\/td>May 17, 2018<\/td>\n<\/tr>\n
Sun Pharma to announce fourth quarter results on 25 May 2018<\/a><\/td>May 11, 2018<\/td>\n<\/tr>\n
Sun Pharma CHC enters anti fungal powder OTC category with ABZORB<\/a><\/td>April 30, 2018<\/td>\n<\/tr>\n
FDEC First Year Report of Malaria Elimination Demonstration Project (MEDP)<\/a><\/td>March 23, 2018<\/td>\n<\/tr>\n
Sun Pharma Announces U.S. FDA Approval of ILUMYA\u2122 (tildrakizumab-asmn)<\/a><\/td>March 21, 2018<\/td>\n<\/tr>\n
ILUMYA\u2122 U.S. Prescribing Information<\/a><\/td>March 21, 2018<\/td>\n<\/tr>\n
ILUMYA\u2122 U.S. Medication Guide<\/a><\/td>March 21, 2018<\/td>\n<\/tr>\n
FY18 Q3 Financial Press Release<\/a><\/td>February 14, 2018<\/td>\n<\/tr>\n
Sun Pharma Science Foundation's Annual Conference and Research Awards Presentation Ceremony<\/a><\/td>February 13, 2018<\/td>\n<\/tr>\n
Sun Pharma to announce third quarter results on February 14, 2018<\/a><\/td>February 02, 2018<\/td>\n<\/tr>\n
Sun Pharma Announces Settlement of Patent Litigation for Generic Linzess in US<\/a><\/td>January 16, 2018<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n\n

[\/et_pb_tab][et_pb_tab title=”2017″ _builder_version=”4.16″ _module_preset=”default” global_colors_info=”{}”]<\/p>\n\n\n\n\n\t\n\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t
Press Release<\/th>Date<\/th>\n<\/tr>\n<\/thead>\n
Sun Pharma Announces US FDA Acceptance of NDA for OTX-101<\/a><\/td>December 27, 2017<\/td>\n<\/tr>\n
FY18 Q2 Financial Result - Transcript<\/a><\/td>December 02, 2017<\/td>\n<\/tr>\n
Sun Pharmaceutical Industries Inc. Issues Voluntary Nationwide Recall of Riomet\u00ae<\/a><\/td>November 24, 2017<\/td>\n<\/tr>\n
FY18 Q2 Financial Press Release<\/a><\/td>November 14, 2017<\/td>\n<\/tr>\n
Sun Pharma to announce second quarter results on November 14, 2017<\/a><\/td>October 31, 2017<\/td>\n<\/tr>\n
Sun Pharma announces US FDA approval for generic Coreg CR\u00ae<\/a><\/td>October 26, 2017<\/td>\n<\/tr>\n
Sun Pharma Odomzo\u00ae (Sonidegib) New Label Approval<\/a><\/td>September 20, 2017<\/td>\n<\/tr>\n
FY18 Q1 Financial Result - Transcript<\/a><\/td>September 15, 2017<\/td>\n<\/tr>\n
FY18 Q1 Financial Press Release<\/a><\/td>August 11, 2017<\/td>\n<\/tr>\n
Sun Pharma to announce first quarter results on August 11, 2017<\/a><\/td>July 26, 2017<\/td>\n<\/tr>\n
Sun Pharma and Samsung BioLogics announce strategic manufacturing tie up for Tildrakizumab<\/a><\/td>July 04, 2017<\/td>\n<\/tr>\n
Sun Pharma and NIV sign agreement to fight Zika, Chikungunya and Dengue<\/a><\/td>June 27, 2017<\/td>\n<\/tr>\n
US FDA approval for generic Zetia\u00ae tablets<\/a><\/td>June 13, 2017<\/td>\n<\/tr>\n
FY17 Q4 Financial Result - Transcript<\/a><\/td>June 13, 2017<\/td>\n<\/tr>\n
FY17 Q4 Financial Press Release<\/a><\/td>May 26, 2017<\/td>\n<\/tr>\n
US FDA Filing Acceptance of Biologics License Application For Tildrakizumab<\/a><\/td>May 24, 2017<\/td>\n<\/tr>\n
Sun Pharma to announce fourth quarter results on May 26, 2017<\/a><\/td>May 15, 2017<\/td>\n<\/tr>\n
Sun Pharma Science Foundation recognizes Indian scientists & young research scholars<\/a><\/td>April 28, 2017<\/td>\n<\/tr>\n
FDEC commences roll-out of Malaria demonstration project<\/a><\/td>April 25, 2017<\/td>\n<\/tr>\n
Sun Pharma Science Foundation Media Invitation<\/a><\/td>April 25, 2017<\/td>\n<\/tr>\n
Almirall and Sun Pharma Announce Regulatory Filing of Tildrakizumab in Europe<\/a><\/td>March 24, 2017<\/td>\n<\/tr>\n
Update on Mohali Facility<\/a><\/td>March 14, 2017<\/td>\n<\/tr>\n
Tildrakizumab Clinical Development Program to be Presented at the 2017 American Academy of Dermatology Meeting<\/a><\/td>March 01, 2017<\/td>\n<\/tr>\n
FY17 Q3 Financial Result - Transcript<\/a><\/td>February 27, 2017<\/td>\n<\/tr>\n
FY17 Q3 Financial Press Release<\/a><\/td>February 14, 2017<\/td>\n<\/tr>\n
Sun Pharma Q3 FY17 financial result on February 14, 2017<\/a><\/td>January 31, 2017<\/td>\n<\/tr>\n
Sun Pharma Announces Positive Topline Results of Confirmatory Phase-3 Clinical Trial for Seciera\u2122 for Treatment of Dry Eye<\/a><\/td>January 04, 2017<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n\n

[\/et_pb_tab][et_pb_tab title=”2016″ _builder_version=”4.16″ _module_preset=”default” global_colors_info=”{}”]<\/p>\n\n\n\n\n\t\n\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t
Press Release<\/th>Date<\/th>\n<\/tr>\n<\/thead>\n
Sun Pharma & Moebius Medical sign deal to develop novel liposomal non-opiod pain product for osteoarthritis<\/a><\/td>December 12, 2016<\/td>\n<\/tr>\n
FY17 Q2 Financial Result - Transcript<\/a><\/td>November 30, 2016<\/td>\n<\/tr>\n
Sun Pharma launches first branded ophthalmic product, BromSite in USA<\/a><\/td>November 28, 2016<\/td>\n<\/tr>\n
Sun Pharma to acquire Biosintez in Russia<\/a><\/td>November 23, 2016<\/td>\n<\/tr>\n
ICMR, Govt of MP and FDEC-India sign tri-party agreement to launch Malaria Free India demonstration project in Mandla district of Madhya Pradesh- English Press Release<\/a><\/td>November 15, 2016
\n<\/td>\n<\/tr>\n
ICMR, Govt of MP and FDEC-India sign tri-party agreement to launch Malaria Free India demonstration project in Mandla district of Madhya Pradesh- Hindi Press Release<\/a><\/td>November 15, 2016
\n<\/td>\n<\/tr>\n
FY17 Q2 Financial Press Release<\/a><\/td>November 10, 2016<\/td>\n<\/tr>\n
Sun Pharma Announces US Launch of Authorized Generics for Olmesartan<\/a><\/td>October 27, 2016<\/td>\n<\/tr>\n
Sun Pharma Q2 FY17 financial result on November 10, 2016<\/a><\/td>October 26, 2016<\/td>\n<\/tr>\n
Sun Pharma to Acquire Ocular Technologies<\/a><\/td>October 26, 2016<\/td>\n<\/tr>\n
Sun Pharma & ICGEB announce new exclusive collaboration to develop novel dengue vaccine for India & Global markets<\/a><\/td>October 19, 2016<\/td>\n<\/tr>\n
Revital H Woman launches \u2018Healthy Conversations\u2019 initiative<\/a><\/td>October 03, 2016<\/td>\n<\/tr>\n
Sun Pharma to Announce Late-Breaking Results for Tildrakizumab<\/a><\/td>October 01, 2016<\/td>\n<\/tr>\n
Sun Pharma announces distribution alliance with Mitsubishi Tanabe Pharma Corporation in Japan<\/a><\/td>September 06, 2016<\/td>\n<\/tr>\n
FY17 Q1 Financial Result - Transcript<\/a><\/td>August 29, 2016<\/td>\n<\/tr>\n
FY17 Q1 Financial Press Release<\/a><\/td>August 12, 2016<\/td>\n<\/tr>\n
Sun Pharma extends Imatinib Mesylate Savings Card program benefits for patients in USA<\/a><\/td>August 08, 2016<\/td>\n<\/tr>\n
Sun Pharma announces US FDA approval for generic Glumetza\u00ae<\/a><\/td>August 02, 2016<\/td>\n<\/tr>\n
Sun Pharma to announce first quarter results on August 12, 2016<\/a><\/td>August 01, 2016<\/td>\n<\/tr>\n
Sun Pharma and Almirall enter into a License Agreement for Tildrakizumab in Europe for Psoriasis<\/a><\/td>July 27, 2016<\/td>\n<\/tr>\n
Sun Pharma announces US FDA approval for generic Crestor\u00ae<\/a><\/td>July 20, 2016<\/td>\n<\/tr>\n
SPARC licenses Elepsia XR to Sun Pharma<\/a><\/td>July 18, 2016<\/td>\n<\/tr>\n
Sun Pharma launches Gemcitabine InfuSMART<\/a><\/td>July 11, 2016<\/td>\n<\/tr>\n
Sun Pharma Announces Buyback of Equity Shares<\/a><\/td>June 23, 2016<\/td>\n<\/tr>\n
FY16 Q4 Financial Result - Transcript<\/a><\/td>June 10, 2016<\/td>\n<\/tr>\n
Sun Pharma focuses on dermatology as additional engine of growth for GCH business-Press Release<\/a><\/td>June 08, 2016<\/td>\n<\/tr>\n
Sun Pharma focuses on dermatology as additional engine of growth for GCH business-Factsheet<\/a><\/td>June 08, 2016<\/td>\n<\/tr>\n
Press Conference Invitation<\/a><\/td>June 06, 2016<\/td>\n<\/tr>\n
Sun Pharma announces divestment of US manufacturing units<\/a><\/td>June 04, 2016<\/td>\n<\/tr>\n
FY16 Q4 Financial Press Release<\/a><\/td>May 30, 2016<\/td>\n<\/tr>\n
Sun Pharma to announce fourth quarter results on May 30, 2016<\/a><\/td>May 19, 2016<\/td>\n<\/tr>\n
Sun Pharma leverages mobile technology to boost treatment compliance amongst asthma patients<\/a><\/td>May 09, 2016<\/td>\n<\/tr>\n
Sun Pharma Announces Positive Results of Two Pivotal Phase-3 Clinical Trials of Tildrakizumab in Patients with Moderate-to-Severe Plaque Psoriasis<\/a><\/td>May 04, 2016<\/td>\n<\/tr>\n
ICGEB & Sun Pharma sign an exclusive agreement to develop novel botanical drug for treatment of Dengue<\/a><\/td>May 04, 2016<\/td>\n<\/tr>\n
ICGEB & Sun Pharma sign an exclusive agreement to develop novel botanical drug for treatment of Dengue - Endorsements <\/a><\/td>May 04, 2016<\/td>\n<\/tr>\n
ICGEB & Sun Pharma sign an exclusive agreement to develop novel botanical drug for treatment of Dengue -Dengue Factsheet <\/a><\/td>May 04, 2016<\/td>\n<\/tr>\n
Media Invitation - Signing of Novel Drug Development Agreement, May 4, 2016 <\/a><\/td>April 29, 2016<\/td>\n<\/tr>\n
ICMR, MoHFW, GoI, GoMP and Sun Pharma announce Public-Private-Partnership for Malaria Free India - Press Release- Malaria Free India <\/a><\/td>April 25, 2016<\/td>\n<\/tr>\n
ICMR, MoHFW, GoI, GoMP and Sun Pharma announce Public-Private-Partnership for Malaria Free India - Malaria Free India public-private-partnership receives global recognition<\/a><\/td>April 25, 2016<\/td>\n<\/tr>\n
ICMR, MoHFW, GoI, GoMP and Sun Pharma announce Public-Private-Partnership for Malaria Free India - Malaria Free India Blue Print<\/a><\/td>April 25, 2016<\/td>\n<\/tr>\n
ICMR, MoHFW, GoI, GoMP and Sun Pharma announce Public-Private-Partnership for Malaria Free India - Malaria Factsheet<\/a><\/td>April 25, 2016<\/td>\n<\/tr>\n
ICMR, MoHFW, GoI, GoMP and Sun Pharma announce Public-Private-Partnership for Malaria Free India - Spokesperson Bios<\/a><\/td>April 25, 2016<\/td>\n<\/tr>\n
Press Conference Invitation, April 25, New Delhi<\/a><\/td>April 21, 2016<\/td>\n<\/tr>\n
Sun Pharma Receives USFDA Approval For BromSite\u2122<\/a><\/td>April 09, 2016<\/td>\n<\/tr>\n
Sun Pharma enters Japanese prescription market<\/a><\/td>March 29, 2016<\/td>\n<\/tr>\n
Sun Pharma and AstraZeneca India enter partnership in Type 2 diabetes<\/a><\/td>March 23, 2016<\/td>\n<\/tr>\n
Video Release - Digital launch of Pepmelt antacid campaign<\/a><\/td>March 11, 2016<\/td>\n<\/tr>\n
Note on Digital launch of Pepmelt antacid campaign<\/a><\/td>March 11, 2016<\/td>\n<\/tr>\n
Sun Pharma Consumer Healthcare Business enhances presence in digestive care<\/a><\/td>March 11, 2016<\/td>\n<\/tr>\n
Sun Pharma Global Consumer Healthcare signs Indian cricket captain MS Dhoni as Revital H brand ambassador<\/a><\/td>March 08, 2016<\/td>\n<\/tr>\n
FY16 Q3 Earnings Call Transcript<\/a><\/td>February 26, 2016<\/td>\n<\/tr>\n
FY16 Q3 Financial Press Release<\/a><\/td>February 12, 2016<\/td>\n<\/tr>\n
Sun Pharma launches Imatinib Mesylate in USA<\/a><\/td>February 01, 2016<\/td>\n<\/tr>\n
Sun Pharma to announce third quarter results on February 12, 2016<\/a><\/td>January 30, 2016<\/td>\n<\/tr>\n
Revital H announces association with Patna Pirates, Kabbadi Team as Official Health Partner<\/a><\/td>January 27, 2016<\/td>\n<\/tr>\n
Transcript - Update on Halol facility<\/a><\/td>January 04, 2016<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n\n

[\/et_pb_tab][et_pb_tab title=”2015″ _builder_version=”4.16″ _module_preset=”default” global_colors_info=”{}”]<\/p>\n\n\n\n\n\t\n\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t
Press Release<\/th>Date<\/th>\n<\/tr>\n<\/thead>\n
Sun Pharma receives Warning Letter for Halol facility<\/a><\/td>December 19, 2015<\/td>\n<\/tr>\n
Sun Pharma announces divestment of US manufacturing unit<\/a><\/td>December 14, 2015<\/td>\n<\/tr>\n
Sun Pharma announces research collaboration with Weizmann Institute of Science, Israel & Health Research Institute of Santiago, Spain for brain therapies<\/a><\/td>December 10, 2015<\/td>\n<\/tr>\n
Sun Pharma announces US FDA approval for generic Gleevec\u00ae<\/a><\/td>December 04, 2015<\/td>\n<\/tr>\n
Sun Pharma announces its association with World Champion Snowboarder Kelly Clark for Absorica\u00ae<\/a><\/td>December 02, 2015<\/td>\n<\/tr>\n
FY16 Q2 Earnings Call Transcript<\/a><\/td>November 27, 2015<\/td>\n<\/tr>\n
FY16 Q2 Financial Press Release<\/a><\/td>November 07, 2015<\/td>\n<\/tr>\n
Sun Pharma Successfully Acquires InSite Vision<\/a><\/td>November 03, 2015<\/td>\n<\/tr>\n
Volini announces Sania Mirza and Sunil Chhetri as brand ambassadors<\/a><\/td>November 03, 2015<\/td>\n<\/tr>\n
Sun Pharma completes tender offer for InSite Vision<\/a><\/td>October 28, 2015<\/td>\n<\/tr>\n
Sun Pharma Q2 & H1 FY16 financial results on November 07, 2015<\/a><\/td>October 26, 2015<\/td>\n<\/tr>\n
Sun Pharma announces Absorica patent litigation settlement<\/a><\/td>October 05, 2015<\/td>\n<\/tr>\n
Sun Pharma commences Tender Offer for Acquisition of InSite Vision<\/a><\/td>September 29, 2015<\/td>\n<\/tr>\n
Strides Arcolab acquires CNS divisions of erstwhile Ranbaxy<\/a><\/td>September 19, 2015<\/td>\n<\/tr>\n
Sun Pharma to acquire InSite Vision<\/a><\/td>September 15, 2015<\/td>\n<\/tr>\n
Sun Pharma announces successful completion of Opiates business acquisition in Australia<\/a><\/td>September 01, 2015<\/td>\n<\/tr>\n
FY16 Q1 Earnings Call Transcript<\/a><\/td>August 25, 2015<\/td>\n<\/tr>\n
Sun Pharma announces US FDA approval for Ximino<\/a><\/td>August 19, 2015<\/td>\n<\/tr>\n
FY16 Q1 Financial Press Release<\/a><\/td>August 11, 2015<\/td>\n<\/tr>\n
Sun Pharma to announce first quarter results on August 11, 2015<\/a><\/td>July 29, 2015<\/td>\n<\/tr>\n
Transcript - Sun Pharma Business Update<\/a><\/td>July 24, 2015<\/td>\n<\/tr>\n
Sun Pharma provides business update<\/a><\/td>July 20, 2015<\/td>\n<\/tr>\n
SPARC Licenses XelprosTM (Latanoprost BAK-free) to Sun Pharma<\/a><\/td>June 09, 2015<\/td>\n<\/tr>\n
Sun Pharma and AstraZeneca enter into distribution agreement for ticagrelor in India<\/a><\/td>June 02, 2015<\/td>\n<\/tr>\n
Sun Pharma to announce fourth quarter FY15 results on May 29, 2015<\/a><\/td>May 15, 2015<\/td>\n<\/tr>\n
Sun Pharma and the Technion form Research Collaboration to Develop New Class of Oncology Drugs<\/a><\/td>April 15, 2015<\/td>\n<\/tr>\n
Sun Pharma announces closure of merger deal with Ranbaxy<\/a><\/td>March 25, 2015<\/td>\n<\/tr>\n
Sun Pharma announces closure of merger deal with Ranbaxy- Profile of Sun Pharma<\/a><\/td>March 25, 2015<\/td>\n<\/tr>\n
Sun Pharma announces closure of merger deal with Ranbaxy- Investor Relations Presentation <\/a><\/td>March 25, 2015<\/td>\n<\/tr>\n
Sun Pharma announces closure of merger deal with Ranbaxy- Factsheet <\/a><\/td>March 25, 2015<\/td>\n<\/tr>\n
Sun Pharma announces closure of merger deal with Ranbaxy- Profile of Chairman & MD <\/a><\/td>March 25, 2015<\/td>\n<\/tr>\n
Sun Pharma announces closure of merger deal with Ranbaxy- Growing Together Film <\/a><\/td>March 25, 2015<\/td>\n<\/tr>\n
Press Conference Webcast: Sun Pharma - Ranbaxy Merger<\/a><\/td>March 25, 2015
\n<\/td>\n<\/tr>\n
Sun Pharma to buy GSK\u2019s Opiates business in Australia<\/a><\/td>March 03, 2015<\/td>\n<\/tr>\n
FY15 Q3 Earning Call Transcript<\/a><\/td>February 24, 2015<\/td>\n<\/tr>\n
Press Release SPIL Financials Q3 FY15<\/a><\/td>February 14, 2015
\n<\/td>\n<\/tr>\n
Sun Pharma to announce third quarter results on February 14, 2015<\/a><\/td>February 09, 2015<\/td>\n<\/tr>\n
Sun Pharma receives US FTC clearance for Ranbaxy acquisition<\/a><\/td>February 02, 2015<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n\n

[\/et_pb_tab][et_pb_tab title=”2014″ _builder_version=”4.16″ _module_preset=”default” global_colors_info=”{}”]<\/p>\n\n\n\n\n\t\n\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t
Press Release<\/th>Date<\/th>\n<\/tr>\n<\/thead>\n
CCI approves Ranbaxy acquisition by Sun Pharma<\/a><\/td>December 08, 2014<\/td>\n<\/tr>\n
Sun Pharma to announce second quarter results on November 13, 2014<\/a><\/td>October 30, 2014<\/td>\n<\/tr>\n
Sun Pharma and Merck & Co. Inc. Enter into Licensing Agreement for Tildrakizumab<\/a><\/td>September 17, 2014<\/td>\n<\/tr>\n
Form IV contained in Schedule II to the Combination Regulations under Sec 29(2) of Competition Act, 2002 (as amended)<\/a><\/td>September 04, 2014<\/td>\n<\/tr>\n
Q1 FY15 Earnings Call Transcript<\/a><\/td>August 23, 2014<\/td>\n<\/tr>\n
Q1 FY15 Financial Press Release<\/a><\/td>August 12, 2014<\/td>\n<\/tr>\n
Sun Pharma to announce first quarter results on August 12, 2014<\/a><\/td>July 30, 2014<\/td>\n<\/tr>\n
Sun Pharma acquires Pharmalucence<\/a><\/td>July 16, 2014<\/td>\n<\/tr>\n
Q4 FY14 Financial Press Release<\/a><\/td>May 29, 2014<\/td>\n<\/tr>\n
Sun Pharma to announce Q4 and FY14 results on May 29, 2014<\/a><\/td>May 16, 2014<\/td>\n<\/tr>\n
Sun Pharma announces settlement of litigation for generic Gleevec\u00ae in US<\/a><\/td>May 15, 2014<\/td>\n<\/tr>\n
Sun Pharma announces manufacturing consolidation<\/a><\/td>May 02, 2014<\/td>\n<\/tr>\n
Transcript Sun Pharma - Ranbaxy Merger Conference Call<\/a><\/td>April 16, 2014<\/td>\n<\/tr>\n
Clarification on Silverstreet Investment in Ranbaxy<\/a><\/td>April 09, 2014<\/td>\n<\/tr>\n
Investor Presentation: Sun Pharma & Ranbaxy merger<\/a><\/td>April 07, 2014<\/td>\n<\/tr>\n
Sun Pharma to acquire Ranbaxy in a US$ 4 billion landmark transaction<\/a><\/td>April 06, 2014<\/td>\n<\/tr>\n
Import Alert for Karkhadi unit from US FDA<\/a><\/td>March 13, 2014<\/td>\n<\/tr>\n
FY14 Q3 Earnings call transcript<\/a><\/td>February 25, 2014<\/td>\n<\/tr>\n
Rekha Sethi appointed as an additional independent director of Sun Pharma Board<\/a><\/td>February 13, 2014<\/td>\n<\/tr>\n
FY14 Q3 Financial Press Release<\/a><\/td>February 13, 2014<\/td>\n<\/tr>\n
Sun Pharma announces US FDA approval for generic Temodar\u00ae<\/a><\/td>February 13, 2014<\/td>\n<\/tr>\n
Sun Pharma to announce third quarter results on February 13, 2014<\/a><\/td>January 29, 2014<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n\n

[\/et_pb_tab][et_pb_tab title=”2013″ _builder_version=”4.16″ _module_preset=”default” global_colors_info=”{}”]<\/p>\n\n\n\n\n\t\n\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t
Press Release<\/th>Date<\/th>\n<\/tr>\n<\/thead>\n
Sun Pharma announces US FDA approval for generic Cymbalta\u00ae<\/a><\/td>December 12, 2013<\/td>\n<\/tr>\n
FY14 Q2 Earnings call transcript<\/a><\/td>November 22, 2013<\/td>\n<\/tr>\n
FY14 Q2 Financial Press Release<\/a><\/td>November 13, 2013<\/td>\n<\/tr>\n
Sun Pharma to announce second quarter results on November 13, 2013<\/a><\/td>October 28, 2013<\/td>\n<\/tr>\n
Sun Pharma and Intrexon Form Joint Venture to Develop New Class of Therapeutics for Ocular Diseases<\/a><\/td>October 01, 2013<\/td>\n<\/tr>\n
Sun Pharma announces USFDA approval for generic Prevacid\u00ae<\/a><\/td>September 14, 2013<\/td>\n<\/tr>\n
FY14 Q1 Financial Press Release<\/a><\/td>August 09, 2013<\/td>\n<\/tr>\n
Sun Pharma to announce first quarter results on August 09, 2013<\/a><\/td>July 23, 2013<\/td>\n<\/tr>\n
Sun Pharma announces USFDA approval for generic Prandin\u00ae<\/a><\/td>July 12, 2013<\/td>\n<\/tr>\n
Sun Pharma settles generic Protonix\u00ae litigation<\/a><\/td>June 12, 2013<\/td>\n<\/tr>\n
FY13 Q4 Earnings Call Transcript<\/a><\/td>June 12, 2013<\/td>\n<\/tr>\n
Sun Pharma announces USFDA approval for generic Depo\u00ae-Testosterone Injection<\/a><\/td>June 04, 2013<\/td>\n<\/tr>\n
Sun Pharma Announces 1:1 Bonus<\/a><\/td>May 28, 2013<\/td>\n<\/tr>\n
Sun Pharma reports strong performance<\/a><\/td>May 28, 2013<\/td>\n<\/tr>\n
Sun Pharma to announce Q4 and FY13 results on May 28, 2013<\/a><\/td>May 17, 2013<\/td>\n<\/tr>\n
Sun Pharma and Taro Announce Termination of Proposed Transaction<\/a><\/td>February 08, 2013<\/td>\n<\/tr>\n
Sun Pharma announces USFDA approval for generic Doxil\u00ae<\/a><\/td>February 05, 2013<\/td>\n<\/tr>\n
Sun Pharma to announce third quarter results on February 08, 2013<\/a><\/td>January 25, 2013<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n\n

[\/et_pb_tab][et_pb_tab title=”2012″ _builder_version=”4.16″ _module_preset=”default” global_colors_info=”{}”]<\/p>\n\n\n\n\n\t\n\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t
Press Release<\/th>Date<\/th>\n<\/tr>\n<\/thead>\n
Successful acquisition of DUSA Pharmaceuticals, Inc.U.S.A.by our subsidiary<\/a><\/td>December 20, 2012<\/td>\n<\/tr>\n
Sun Pharma acquires URL generic business from Takeda<\/a><\/td>December 17, 2012<\/td>\n<\/tr>\n
Sun Pharma to acquire DUSA Pharmaceuticals, Inc.<\/a><\/td>November 08, 2012<\/td>\n<\/tr>\n
Sun Pharma to announce second quarter results on November 08, 2012<\/a><\/td>October 22, 2012<\/td>\n<\/tr>\n
Sun Pharma to take Taro Private<\/a><\/td>August 13, 2012<\/td>\n<\/tr>\n
Sun Pharma to announce first quarter results on August 10, 2012<\/a><\/td>July 30, 2012<\/td>\n<\/tr>\n
Israel Makov appointed chairman of Sun Pharma Board<\/a><\/td>May 29, 2012<\/td>\n<\/tr>\n
Sun Pharma announces USFDA approval for generic Astelin\u00ae Nasal Spray<\/a><\/td>May 24, 2012<\/td>\n<\/tr>\n
Sun Pharma to announce Q4 and FY12 results on May 29, 2012<\/a><\/td>May 15, 2012<\/td>\n<\/tr>\n
Sun Pharma announces USFDA approval for generic Zyprexa\u00ae tablets<\/a><\/td>April 24, 2012<\/td>\n<\/tr>\n
Favorable Ruling by United States Supreme Court on Prandin\u00ae Litigation<\/a><\/td>April 18, 2012<\/td>\n<\/tr>\n
Sun Pharma announces USFDA approval for generic Seroquel\u00ae tablets<\/a><\/td>March 28, 2012<\/td>\n<\/tr>\n
Sun Pharma announces USFDA approval for generic Zyprexa Zydis\u00ae tablets<\/a><\/td>February 29, 2012<\/td>\n<\/tr>\n
Sun Pharma: An update on generic Protonix\u00ae litigation<\/a><\/td>February 15, 2012<\/td>\n<\/tr>\n
Sun Pharma to announce Q3 FY12 results on February 13, 2012<\/a><\/td>January 31, 2012<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n\n

[\/et_pb_tab][et_pb_tab title=”2011″ _builder_version=”4.16″ _module_preset=”default” global_colors_info=”{}”]<\/p>\n\n\n\n\n\t\n\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t
Press Release<\/th>Date<\/th>\n<\/tr>\n<\/thead>\n
Sun Pharma announces USFDA approval for generic Ultram\u00ae ER tablets<\/a><\/td>December 09, 2011<\/td>\n<\/tr>\n
Sun Pharma to announce Q2 FY12 results on November 13, 2011<\/a><\/td>November 03, 2011<\/td>\n<\/tr>\n
Sun Pharma announces USFDA approval for generic Cardizem CD\u00ae<\/a><\/td>October 31, 2011<\/td>\n<\/tr>\n
Sun Pharma subsidiary resolves USFDA warning letter<\/a><\/td>September 19, 2011<\/td>\n<\/tr>\n
Sun Pharma announces USFDA tentative approval for generic Plavix\u00ae tablets<\/a><\/td>July 29, 2011<\/td>\n<\/tr>\n
Sun Pharma to announce Q1 FY12 results on July 28, 2011<\/a><\/td>July 20, 2011<\/td>\n<\/tr>\n
Sun Pharma announces USFDA approval for generic Uroxatral\u00ae ER tablets Company gets 180 day marketing exclusivity on first-to-file ANDA with para IV certification<\/a><\/td>July 19, 2011<\/td>\n<\/tr>\n
Sun Pharma announces USFDA approval for generic Imitrex\u00ae injection<\/a><\/td>June 21, 2011<\/td>\n<\/tr>\n
Sun Pharma to announce Q4 and FY11 financial results on May 28, 2011<\/a><\/td>May 14, 2011<\/td>\n<\/tr>\n
Sun Pharma announces USFDA approval for DOCEFREZ (docetaxel) for Injection<\/a><\/td>May 04, 2011<\/td>\n<\/tr>\n
Call Transcript: Sun Pharma & Merck JV announcement<\/a><\/td>April 20, 2011<\/td>\n<\/tr>\n
Sun Pharma and Merck Establish joint venture to develop and commercialize novel formulations and combinations of medicines<\/a><\/td>April 11, 2011<\/td>\n<\/tr>\n
Sun Pharma announces USFDA approval for generic Razadyne\u00ae ER<\/a><\/td>February 03, 2011<\/td>\n<\/tr>\n
Sun Pharma to announce Q3FY11 results on Jan 31, 2011<\/a><\/td>January 18, 2011<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n\n

[\/et_pb_tab][et_pb_tab title=”2010″ _builder_version=”4.16″ _module_preset=”default” global_colors_info=”{}”]<\/p>\n\n\n\n\n\t\n\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t
Press Release<\/th>Date<\/th>\n<\/tr>\n<\/thead>\n
Sun Pharma announces USFDA tentative approval for generic Boniva\u00ae<\/a><\/td>December 30, 2010<\/td>\n<\/tr>\n
Sun Pharma announces USFDA tentative approval for generic Aricept\u00ae<\/a><\/td>November 30, 2010<\/td>\n<\/tr>\n
Sun Pharma announces USFDA tentative approval for generic Cymbalta\u00ae<\/a><\/td>November 24, 2010<\/td>\n<\/tr>\n
Sun Pharma announces USFDA approval for generic Diltiazem ER\u00ae<\/a><\/td>November 18, 2010<\/td>\n<\/tr>\n
Sun Pharma announces USFDA approval for generic Clarinex\u00ae<\/a><\/td>November 18, 2010<\/td>\n<\/tr>\n
Sun Pharma announces USFDA tentative approval for generic Stalevo\u00ae<\/a><\/td>October 01, 2010<\/td>\n<\/tr>\n
Sun Pharma announces USFDA tentative approval for generic Crestor\u00ae<\/a><\/td>September 29, 2010<\/td>\n<\/tr>\n
Sun Pharma announces expiration of subsequent offering period<\/a><\/td>September 29, 2010<\/td>\n<\/tr>\n
Sun Pharma announces USFDA tentative approval for generic Rilutek\u00ae<\/a><\/td>September 28, 2010<\/td>\n<\/tr>\n
Sun Pharma acquires controlling stake in Taro<\/a><\/td>September 21, 2010<\/td>\n<\/tr>\n
Sun Pharmaceutical announces expiration of offer for Taro<\/a><\/td>September 15, 2010<\/td>\n<\/tr>\n
Supreme court of Israel rules in favor of Sun Pharma<\/a><\/td>September 07, 2010<\/td>\n<\/tr>\n
Sun Pharma announces USFDA approval for generic Strattera\u00ae Capsules<\/a><\/td>August 31, 2010<\/td>\n<\/tr>\n
Sun Pharma subsidiary receives warning letter from USFDA<\/a><\/td>August 31, 2010<\/td>\n<\/tr>\n
Sun Pharma announces USFDA approval for generic Venlafaxine ER\u00ae Tablets<\/a><\/td>August 19, 2010<\/td>\n<\/tr>\n
US appeals court rules Gemzar\u00ae patent invalid<\/a><\/td>July 29, 2010<\/td>\n<\/tr>\n
Sun Pharma: an update on generic Protonix litigation\u00ae <\/a><\/td>July 17, 2010<\/td>\n<\/tr>\n
Sun Pharma announces USFDA approval for generic Flomax\u00ae<\/a><\/td>July 16, 2010<\/td>\n<\/tr>\n
US district court rules in favor of Sun Pharmaceutical dismisses all of Taro's claims<\/a><\/td>July 15, 2010<\/td>\n<\/tr>\n
Sun Pharma to announce Q1FY11 results on July 28, 2010<\/a><\/td>July 13, 2010<\/td>\n<\/tr>\n
Sun Pharma: an update on generic Eloxatin\u00ae injection<\/a><\/td>June 26, 2010<\/td>\n<\/tr>\n
Sun Pharma settles litigation over generic Stalevo\u00c2\u00ae and Comtan\u00ae<\/a><\/td>June 22, 2010<\/td>\n<\/tr>\n
Sun Pharma announces USFDA approval for generic Optivar\u00ae<\/a><\/td>June 21, 2010<\/td>\n<\/tr>\n
Sun Pharma announces USFDA approval for generic Xanax\u00ae Tablets<\/a><\/td>June 18, 2010<\/td>\n<\/tr>\n
Sun Pharma announces USFDA approval for generic Keppra\u00c2\u00ae Injection, levetiracetam\u00ae injection<\/a><\/td>June 17, 2010<\/td>\n<\/tr>\n
Sun Pharma: an update on generic Protonix\u00ae litigation<\/a><\/td>April 24, 2010<\/td>\n<\/tr>\n
Sun Pharma announces USFDA tentative approval for generic Namenda\u00ae tablets<\/a><\/td>April 10, 2010<\/td>\n<\/tr>\n
Sun Pharma announces USFDA approval for generic Wellbutrin\u00ae SR extended release tablets<\/a><\/td>April 08, 2010<\/td>\n<\/tr>\n
Sun Pharma announces USFDA approval for generic Prometh\u00ae syrup<\/a><\/td>March 18, 2010<\/td>\n<\/tr>\n
Sun Pharma sends letter to directors of Taro<\/a><\/td>January 11, 2010<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n\n

[\/et_pb_tab][et_pb_tab title=”2009″ _builder_version=”4.16″ _module_preset=”default” global_colors_info=”{}”]<\/p>\n\n\n\n\n\t\n\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t
Press Release<\/th>Date<\/th>\n<\/tr>\n<\/thead>\n
Generic Eloxatin\u00ae and Imitrex\u00ae approval: shares 180-day marketing drug exclusivity for generic Eloxatin\u00ae<\/a><\/td>August 11, 2009<\/td>\n<\/tr>\n
Sun Pharma signs agreement with MedImmune for generic Ethyol\u00ae<\/a><\/td>August 03, 2009<\/td>\n<\/tr>\n
Sun Pharma to license key Escitalopram\u00ae patent applications to Lundbeck\u00ae<\/a><\/td>July 10, 2009<\/td>\n<\/tr>\n
Sun Pharma announces USFDA approval for generic Casodex\u00ae tablets<\/a><\/td>July 07, 2009<\/td>\n<\/tr>\n
Conference call transcript - FDA seizure at Caraco, June 2009s<\/a><\/td>July 02, 2009<\/td>\n<\/tr>\n
Sun Pharma announces USFDA tentative approval for generic Optivar\u00ae<\/a><\/td>July 02, 2009<\/td>\n<\/tr>\n
Sun Pharma to hold conference call on June 27, 2009<\/a><\/td>June 26, 2009<\/td>\n<\/tr>\n
Sun Pharma announces USFDA approval for generic Accupril\u00ae tablets<\/a><\/td>June 19, 2009<\/td>\n<\/tr>\n
Sun Pharma to announce FY09 results on May 30. Earnings call on June 1, 2009.<\/a><\/td>May 18, 2009<\/td>\n<\/tr>\n
Sun Pharma announces USFDA tentative approval for generic Uroxatral\u00ae extended release tablets.<\/a><\/td>May 07, 2009<\/td>\n<\/tr>\n
Sun Pharma announces USFDA approval to market generic Roxicodone\u00ae tablets.<\/a><\/td>April 13, 2009<\/td>\n<\/tr>\n
Sun Pharma announces USFDA approval to market generic Topamax\u00ae tablets<\/a><\/td>March 28, 2009<\/td>\n<\/tr>\n
Sun Pharma extends tender offer for Taro to April 3, 2009<\/a><\/td>March 20, 2009<\/td>\n<\/tr>\n
Sun Pharma extends tender offer for Taro to Mar 20, 2009<\/a><\/td>March 06, 2009<\/td>\n<\/tr>\n
Sun Pharma extends tender offer for Taro to March 6, 2009<\/a><\/td>January 29, 2009<\/td>\n<\/tr>\n
Sun Pharma Q3 results on Jan 30; conf call on Jan 31<\/a><\/td>January 24, 2009<\/td>\n<\/tr>\n
Sun Pharmaceutical extends tender offer for Taro to January 30, 2009<\/a><\/td>January 07, 2009<\/td>\n<\/tr>\n
Sun Pharma receives USFDA approvals for 4 generic products; company receives its first controlled substance product approval<\/a><\/td>January 07, 2009<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n\n

[\/et_pb_tab][et_pb_tab title=”2008″ _builder_version=”4.16″ _module_preset=”default” global_colors_info=”{}”]<\/p>\n\n\n\n\n\t\n\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t
Press Release<\/th>Date<\/th>\n<\/tr>\n<\/thead>\n
Sun Pharmaceutical extends tender offer for Taro December 19, 2008<\/a><\/td>January 9, 2009<\/td>\n<\/tr>\n
Sun Pharma update on ANDA for generic Effexor XR: USFDA grants Osmotica's citizen petition<\/a><\/td>November 27, 2008<\/td>\n<\/tr>\n
Sun Pharma subsidiary acquires 100% of Chattem Chemicals, Inc. a US based DEA registered narcotic API importer & producer<\/a><\/td>November 25, 2008<\/td>\n<\/tr>\n
Sun Pharmaceutical extends tender offer for Taro to Dec 19, 2008<\/a><\/td>November 07, 2008<\/td>\n<\/tr>\n
Sun Pharmaceutical announces USFDA approval to market generic Sinemet\u00ae tablets<\/a><\/td>November 05, 2008<\/td>\n<\/tr>\n
Sun Pharma to announce Q2 and H1 2008-09 results on Oct 25, 2008<\/a><\/td>October 15, 2008<\/td>\n<\/tr>\n
Sun Pharma extends tender offer for Taro<\/a><\/td>October 03, 2008<\/td>\n<\/tr>\n
Sun Pharma announces USFDA approval to market generic Paraplatin\u00ae injection<\/a><\/td>September 23, 2008<\/td>\n<\/tr>\n
Sun Pharma gets USFDA approval for generic Fosamax\u00ae tablets<\/a><\/td>September 12, 2008<\/td>\n<\/tr>\n
Sun Pharmaceutical extends tender offer for Taro<\/a><\/td>September 03, 2008<\/td>\n<\/tr>\n
Sun to file amendment to tender offer for Taro waiving certain conditions<\/a><\/td>August 27, 2008<\/td>\n<\/tr>\n
Tel-Aviv court rules in favor of Sun Pharmaceutical; no special tender offer neccessary in Taro offer<\/a><\/td>August 27, 2008<\/td>\n<\/tr>\n
Sun Pharmaceutical Sends Second Letter to Taro Pharmaceutical Regarding Taro\u2019s Irish Subsidiary<\/a><\/td>August 25, 2008<\/td>\n<\/tr>\n
Sun Pharma announces US FTC clearance<\/a><\/td>August 14, 2008<\/td>\n<\/tr>\n
Sun Pharma gets USFDA approval for generic Depakote\u00ae delayed release tablets<\/a><\/td>July 30, 2008<\/td>\n<\/tr>\n
Sun Pharma reaffirms commitment to Taro facilities and employees<\/a><\/td>July 28, 2008<\/td>\n<\/tr>\n
Sun Pharma extends tender offer for Taro<\/a><\/td>July 14, 2008<\/td>\n<\/tr>\n
Sun Pharma commences tender offer for Taro shares<\/a><\/td>June 30, 2008<\/td>\n<\/tr>\n
Sun Pharma exercises its options to acquire the shares of the controlling shareholders of Taro Pharma<\/a><\/td>June 26, 2008<\/td>\n<\/tr>\n
Sun Pharma comments on Taro's potential sale of its Irish operations<\/a><\/td>June 05, 2008<\/td>\n<\/tr>\n
Sun Pharma responds to Taros purported termination of merger agreement<\/a><\/td>May 29, 2008<\/td>\n<\/tr>\n
Sun Pharma receives notice for termination of merger from Taro<\/a><\/td>May 28, 2008<\/td>\n<\/tr>\n
Q4 2007-08 results on 30 May, 2008; earnings call on 30 May, 2008 at 6:30 PM IST<\/a><\/td>May 17, 2008<\/td>\n<\/tr>\n
Sun Pharmaceutical announces launch of generic Ethyol \u00ae (180 days exclusivity)<\/a><\/td>March 31, 2008<\/td>\n<\/tr>\n
Sun Pharmaceutical announces USFDA approval to market generic Tessalon \u00ae<\/a><\/td>March 21, 2008<\/td>\n<\/tr>\n
Sun Pharmaceutical announces USFDA approval to market generic Cerebyx \u00ae<\/a><\/td>March 19, 2008<\/td>\n<\/tr>\n
Sun Pharmaceutical announces USFDA approval to market generic Ethyol \u00ae (With 180 day marketing exclusivity)<\/a><\/td>March 15, 2008<\/td>\n<\/tr>\n
Sun Pharma gets USFDA tentative approval for generic Gemzar \u00ae injection<\/a><\/td>March 05, 2008<\/td>\n<\/tr>\n
Sun Pharma gets USFDA approval to market generic Demadex \u00ae Tablets<\/a><\/td>February 27, 2008<\/td>\n<\/tr>\n
Sun Pharma buys additional 9.4% stake in Taro Pharma from Brandes<\/a><\/td>February 19, 2008<\/td>\n<\/tr>\n
Sun Pharma gets USFDA tentative approval for generic Depakote \u00ae delayed release tablets<\/a><\/td>February 14, 2008<\/td>\n<\/tr>\n
Sun Pharma launches generic Protonix \u00ae Tablets<\/a><\/td>January 30, 2008<\/td>\n<\/tr>\n
Sun Pharma Q3 2007-08 results on 30 Jan, 2008; earnings call on January 31, 2008 on 10:00 am IST<\/a><\/td>January 16, 2008<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n\n

[\/et_pb_tab][et_pb_tab title=”2007″ _builder_version=”4.16″ _module_preset=”default” global_colors_info=”{}”]<\/p>\n\n\n\n\n\t\n\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t
Press Release<\/th>Date<\/th>\n<\/tr>\n<\/thead>\n
Sun Pharma announces settlement of litigation over generic Exelon\u00ae<\/a><\/td>December 06, 2007<\/td>\n<\/tr>\n
Sun Pharma announces USFDA approval to market generic Exelon\u00ae Capsules<\/a><\/td>October 23, 2007<\/td>\n<\/tr>\n
Sun Pharma receives will-not-sue covenant on generic Effexor XR \u00ae ANDA<\/a><\/td>October 16, 2007<\/td>\n<\/tr>\n
Sun Pharma Q2 2007-08 results on Oct 25, 2007; earnings call on Oct 26 at 10 am IST<\/a><\/td>October 09, 2007<\/td>\n<\/tr>\n
Sun Pharma announces USFDA approval to market generic Trileptal\u00ae Tablets, 180 day marketing exclusivity<\/a><\/td>October 10, 2007<\/td>\n<\/tr>\n
Sun Pharma announces USFDA approval to market generic Protonix Tablets - Company gets its first 180 day marketing exclusivity on a first-to-file ANDA with para IV certification<\/a><\/td>September 11, 2007<\/td>\n<\/tr>\n
USFDA grants tentative approval for Sun Pharma's ANDA for Galantamine tablets<\/a><\/td>August 30, 2007<\/td>\n<\/tr>\n
Sun Pharma announces USFDA approval for Sinemet CR, an extended release version of Carbidopa with Levodopa<\/a><\/td>August 25, 2007<\/td>\n<\/tr>\n
Sun Pharma announces USFDA approval to market generic Octreotide injection<\/a><\/td>August 18, 2007<\/td>\n<\/tr>\n
Investor presentation<\/a><\/td>July 26, 2007<\/td>\n<\/tr>\n
Notice of extraordinary general meeting on July 28, 2007<\/a><\/td>July 19, 2007<\/td>\n<\/tr>\n
Sun Pharma to acquire Taro Pharma in a USD 454 million deal<\/a><\/td>May 21, 2007<\/td>\n<\/tr>\n
Sales growth 30%, profit increased 35%, R&D spend Rs. 2924 million<\/a><\/td>May 18, 2007<\/td>\n<\/tr>\n
Apportionment of cost between SPIL and SPARC<\/a><\/td>May 14, 2007<\/td>\n<\/tr>\n
Way forward on demerger<\/a><\/td>May 14, 2007<\/td>\n<\/tr>\n
Transcript of management presentation on NCE and NDDS<\/a><\/td>March 26, 2007<\/td>\n<\/tr>\n
Management presentation on NCE and NDDS<\/a><\/td>March 16, 2007<\/td>\n<\/tr>\n
Announcement of a management presentation on NCE and NDDS<\/a><\/td>March 12, 2007<\/td>\n<\/tr>\n
Q3 sales up 27%, net profit up 36%<\/a><\/td>January 29, 2007<\/td>\n<\/tr>\n
3rd Quarter 2006-07 results on 29 Jan 2007, call on 30 Jan at 0930<\/a><\/td>January 15, 2007<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n\n

[\/et_pb_tab][et_pb_tab title=”2006″ _builder_version=”4.16″ _module_preset=”default” global_colors_info=”{}”]<\/p>\n\n\n\n\n\t\n\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t
Press Release<\/th>Date<\/th>\n<\/tr>\n<\/thead>\n
Sun Pharma's lead molecule enters Phase II in the US<\/a><\/td>October 20, 2006<\/td>\n<\/tr>\n
Second quarter results on Oct. 19<\/a><\/td>October 09, 2006<\/td>\n<\/tr>\n
Conference call transcript- innovative R&D demerger<\/a><\/td>February 10, 2006<\/td>\n<\/tr>\n
Sun Pharma Board Approves Demerger Of Innovative R&D<\/a><\/td>February 10, 2006<\/td>\n<\/tr>\n
Board clears demerger proposal<\/a><\/td>February 09, 2006<\/td>\n<\/tr>\n
Conference call: Demerger of Innovative R&D<\/a><\/td>February 07, 2006<\/td>\n<\/tr>\n
Sun Pharma's board to meet Jan 30: Q3 results<\/a><\/td>January 17, 2006<\/td>\n<\/tr>\n
DMF approval for Metaprolol tartrate received<\/a><\/td>February 14, 2003<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n\n

[\/et_pb_tab][et_pb_tab title=”2005″ _builder_version=”4.16″ _module_preset=”default” global_colors_info=”{}”]<\/p>\n\n\n\n\n\t\n\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t
Press Release<\/th>Date<\/th>\n<\/tr>\n<\/thead>\n
Sun Pharma closes Able Labs acquisition in the US<\/a><\/td>December 23, 2005<\/td>\n<\/tr>\n
Sun Pharma H1 results on Oct 28\"<\/a><\/td>October 18, 2005<\/td>\n<\/tr>\n
Sun Pharma shares plans: recent Hungarian and US acquisitions<\/a><\/td>October 04, 2005<\/td>\n<\/tr>\n
Sun Pharma buys manufacturing facility in Bryan, Ohio<\/a><\/td>September 14, 2005<\/td>\n<\/tr>\n
Sun Pharma to buy manufacturing site in Hungary<\/a><\/td>August 10, 2005<\/td>\n<\/tr>\n
Sun Pharma Q1 post results conference call on Thursday July 28 at 11am IST<\/a><\/td>July 28, 2005<\/td>\n<\/tr>\n
Sun Pharma Board to meet July 27: Q1 results<\/a><\/td>July 18, 2005<\/td>\n<\/tr>\n
Sun Pharma Board to meet June 6: Q4 results<\/a><\/td>May 30, 2005<\/td>\n<\/tr>\n
Sun Pharma to donate hostel for medical college<\/a><\/td>May 12, 2005<\/td>\n<\/tr>\n
Sun Pharma shares guidance for 2005-2006<\/a><\/td>May 06, 2005<\/td>\n<\/tr>\n
Quarter 4 conference call on April 28 at 10am<\/a><\/td>April 28, 2005<\/td>\n<\/tr>\n
Q3 result conference Call<\/a><\/td>January 21, 2005<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n\n

[\/et_pb_tab][et_pb_tab title=”2004″ _builder_version=”4.16″ _module_preset=”default” global_colors_info=”{}”]<\/p>\n\n\n\n\n\t\n\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t
Press Release<\/th>Date<\/th>\n<\/tr>\n<\/thead>\n
President to inaugurate Sun Pharma's research center<\/a><\/td>December 07, 2004<\/td>\n<\/tr>\n
Sun Pharma declares interim dividend<\/a><\/td>November 29, 2004<\/td>\n<\/tr>\n
Sun Pharma completes $275 mill FCCB<\/a><\/td>November 27, 2004<\/td>\n<\/tr>\n
Sun Pharma launches $225 mill FCCB Issue<\/a><\/td>November 18, 2004<\/td>\n<\/tr>\n
Sun Pharma board to meet on Oct 21: first half results<\/a><\/td>October 18, 2004<\/td>\n<\/tr>\n
Sun Pharma to buy 3 US brands for $5.4 mill Entry in brand market in North America<\/a><\/td>September 23, 2004<\/td>\n<\/tr>\n
Fire in Unit 1 at Panoli<\/a><\/td>August 06, 2004<\/td>\n<\/tr>\n
Sun Pharma: flood at plant sites<\/a><\/td>August 04, 2004<\/td>\n<\/tr>\n
Sun Pharma Q1 post results conference call on Monday, August 2 at 11.00 am<\/a><\/td>August 02, 2004<\/td>\n<\/tr>\n
Sun Pharma announces swap ratio for Phlox Pharma merger<\/a><\/td>July 31, 2004<\/td>\n<\/tr>\n
Sun Pharma board to meet July 31: Q1 results<\/a><\/td>July 19, 2004<\/td>\n<\/tr>\n
Sun Pharma to acquire a bulk active company : Phlox Pharma has EDMF approval, UKMCA \/ USFDA compliant plant<\/a><\/td>July 06, 2004<\/td>\n<\/tr>\n
Fire put out at Sun Pharma's corporate offices<\/a><\/td>June 21, 2004<\/td>\n<\/tr>\n
Buyback of 6% cumulative redeemable preference shares<\/a><\/td>May 27, 2004
\n
\n<\/td>\n<\/tr>\n
Sun Pharma's bulk active and tablet manufacturing factories are cleared by USFDA<\/a><\/td>May 26, 2004<\/td>\n<\/tr>\n
Letter to the stock exchange for result correction<\/a><\/td>May 17, 2004<\/td>\n<\/tr>\n
Record date for bonus is May 29<\/a><\/td>May 06, 2004<\/td>\n<\/tr>\n
No such proposal, says Sun Pharma Bloomberg story titled \"Sun Pharma plans to acquire remaining stake in Caraco\"<\/a><\/td>April 23, 2004<\/td>\n<\/tr>\n
Sun Pharma Q4 post results conference call on Thursday April 22, 12 noon<\/a><\/td>April 22, 2004<\/td>\n<\/tr>\n
1:1 Bonus announced exports jumps 48%; powers profit growth PAT up 21.2%, total income up 20.8%, R&D expense 11.7% of turnover<\/a><\/td>April 21, 2004
\n
\n<\/td>\n<\/tr>\n
Sun Pharma board to meet April 21: Audited financial results<\/a><\/td>April 13, 2004<\/td>\n<\/tr>\n
Sun Pharma to raise $350mill, EGM announced<\/a><\/td>April 08, 2004<\/td>\n<\/tr>\n
Sun Pharma board to meet; to consider issue of convertible debentures<\/a><\/td>April 02, 2004<\/td>\n<\/tr>\n
Sun Pharma hikes stake in Caraco to 63.14%\"<\/a><\/td>March 13, 2004<\/td>\n<\/tr>\n
Clarification on news items regarding acquisition of HAL<\/a><\/td>March 09, 2004<\/td>\n<\/tr>\n
Sun Pharma purchases additional stake in Caraco to hold over 60 % equity<\/a><\/td>February 03, 2004<\/td>\n<\/tr>\n
Mr. Ashwin Dani joins Sun Pharma board<\/a><\/td>February 02, 2004<\/td>\n<\/tr>\n
Q3 results conf call Jan 28\/5pm IST<\/a><\/td>January 28, 2004<\/td>\n<\/tr>\n
Unaudited Q3 numbers on January 28<\/a><\/td>January 19, 2004<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n\n

[\/et_pb_tab][et_pb_tab title=”2003″ _builder_version=”4.16″ _module_preset=”default” global_colors_info=”{}”]<\/p>\n\n\n\n\n\t\n\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t
Press Release<\/th>Date<\/th>\n<\/tr>\n<\/thead>\n
Sun Pharma H1 post results conference call on Wednesday October 22, 11am<\/a><\/td>October 22, 2003<\/td>\n<\/tr>\n
Sun Pharma to announce unaudited H1 numbers on October 21<\/a><\/td>October 16, 2003<\/td>\n<\/tr>\n
Sun Pharma to announce unaudited q1 numbers on July 28<\/a><\/td>July 16, 2003<\/td>\n<\/tr>\n
Sun Pharma conference call after the Q1 results on Monday, July 28<\/a><\/td>July 16, 2003<\/td>\n<\/tr>\n
Conference call after the Q1 results on Monday, July 28<\/a><\/td>July 17, 2003<\/td>\n<\/tr>\n
Q4 conf call on May5<\/a><\/td>May 05, 2003<\/td>\n<\/tr>\n
Sun Pharma to announce audited q4 numbers on May 3<\/a><\/td>April 25, 2003<\/td>\n<\/tr>\n
DMF approval for Metaprolol tartrate received<\/a><\/td>February 14, 2003<\/td>\n<\/tr>\n
Q3 conf call announcement for Jan 30<\/a><\/td>January 30, 2003<\/td>\n<\/tr>\n
Q3 numbers on January 30<\/a><\/td>January 20, 2003<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n\n

[\/et_pb_tab][et_pb_tab title=”2002″ _builder_version=”4.16″ _module_preset=”default” global_colors_info=”{}”]<\/p>\n\n\n\n\n\t\n\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t
Press Release<\/th>Date<\/th>\n<\/tr>\n<\/thead>\n
EGM clears resolutions for split, buyback<\/a><\/td>December 20, 2002<\/td>\n<\/tr>\n
Sun Pharma board proposes buyback plan<\/a><\/td>October 28, 2002<\/td>\n<\/tr>\n
Q2 results on October 28, 2002<\/a><\/td>October 21, 2002<\/td>\n<\/tr>\n
Biostudy volunteer in hospital with pneumonia<\/a><\/td>September 10, 2002<\/td>\n<\/tr>\n
Mr Keki Mistry joins Sun Pharma's board of directors<\/a><\/td>August 29, 2002<\/td>\n<\/tr>\n
AGM approves bonus preference<\/a><\/td>August 28, 2002<\/td>\n<\/tr>\n
Conference call after the Q1 unaudited numbers on Monday, July 22<\/a><\/td>July 22, 2002<\/td>\n<\/tr>\n
Sun Pharma launches anticancer with novel biodegradable microsphere technology product readily available at distribution centers, first time in India<\/a><\/td>July 16, 2002<\/td>\n<\/tr>\n
Sun Pharma announces Bonus Preference Shares carrying coupon of 6% in ratio of 4 shares of Re 1\/- each per 1 equity share held<\/a><\/td>June 28, 2002<\/td>\n<\/tr>\n
Sun Pharma announces audited numbers, dividend, bonus preference, M J Pharma swap record date<\/a><\/td>May 31, 2002<\/td>\n<\/tr>\n
Sun Pharmas board to meet: audited accounts, MJ Pharma merger<\/a><\/td>May 27, 2002<\/td>\n<\/tr>\n
Earnings conference call<\/a><\/td>April 23, 2002<\/td>\n<\/tr>\n
Offer letter to shareholders-regional stock exchanges delisting<\/a><\/td>March 30, 2002<\/td>\n<\/tr>\n
Sun Pharma's new plant at Dadra commences operations<\/a><\/td>March 28, 2002<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n\n

[\/et_pb_tab][et_pb_tab title=”2001″ _builder_version=”4.16″ _module_preset=”default” global_colors_info=”{}”]<\/p>\n\n\n\n\n\t\n\n\t\n\t\n\t\n\t\n\t
Press Release<\/th>Date<\/th>\n<\/tr>\n<\/thead>\n
Sun Pharma launches Smoquit<\/a><\/td>August 10, 2001<\/td>\n<\/tr>\n
Hasmukh Shah joins Sun Pharma board<\/a><\/td>March 23, 2001<\/td>\n<\/tr>\n
Sun Pharma board announces 1:500 ratio for PDC<\/a><\/td>February 26, 2001<\/td>\n<\/tr>\n
Board to meet to consider merger of Pradeep Drugs<\/a><\/td>February 10, 2001<\/td>\n<\/tr>\n
Sun Pharma clarifies on news stories.<\/a><\/td>January 20, 2001<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n\n

 <\/p>\n

[\/et_pb_tab][et_pb_tab title=”2000″ _builder_version=”4.16″ _module_preset=”default” global_colors_info=”{}”]<\/p>\n\n\n\n\n\t\n\n\t\n\t\n\t\n\t
Press Release<\/th>Date<\/th>\n<\/tr>\n<\/thead>\n
Sun Pharma board to consider merger of export subsidiary<\/a><\/td>March 31, 2000<\/td>\n<\/tr>\n
Sun Pharma declares 40% second interim dividend<\/a><\/td>March 18, 2000<\/td>\n<\/tr>\n
Sun Pharma announces bonus<\/a><\/td>February 01, 2000<\/td>\n<\/tr>\n
Sun Pharma board to consider bonus on Feb 1<\/a><\/td>January 21, 2000<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n\n

[\/et_pb_tab][et_pb_tab title=”1999″ _builder_version=”4.16″ _module_preset=”default” global_colors_info=”{}”]<\/p>\n\n\n\n\n\t\n\n\t\n\t\n\t\n\t\n\t\n\t
Press Release<\/th>Date<\/th>\n<\/tr>\n<\/thead>\n
Sun Pharma - Milmet Labs merger<\/a><\/td>November 26, 1999<\/td>\n<\/tr>\n
Sun Pharma declares 60% interim dividend<\/a><\/td>November 06, 1999<\/td>\n<\/tr>\n
Sun Pharma to set up new research campus in Chennai<\/a><\/td>October 25, 1999<\/td>\n<\/tr>\n
CLARIFICATION- No intimation from BIFR<\/a><\/td>September 11, 1999<\/td>\n<\/tr>\n
CLARIFICATION Chennai Plant<\/a><\/td>August 18, 1999<\/td>\n<\/tr>\n
BIFR Okays GLOL merger<\/a><\/td>April 08, 1999<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n\n

[\/et_pb_tab][\/et_pb_tabs][\/et_pb_column][\/et_pb_row][\/et_pb_section][et_pb_section fb_built=”1″ _builder_version=”4.16″ _module_preset=”default” da_disable_devices=”off|off|off” global_colors_info=”{}” da_is_popup=”off” da_exit_intent=”off” da_has_close=”on” da_alt_close=”off” da_dark_close=”off” da_not_modal=”on” da_is_singular=”off” da_with_loader=”off” da_has_shadow=”on”][\/et_pb_section][et_pb_section fb_built=”1″ _builder_version=”4.16″ _module_preset=”default” da_disable_devices=”off|off|off” global_colors_info=”{}” da_is_popup=”off” da_exit_intent=”off” da_has_close=”on” da_alt_close=”off” da_dark_close=”off” da_not_modal=”on” da_is_singular=”off” da_with_loader=”off” da_has_shadow=”on”][\/et_pb_section][et_pb_section fb_built=”1″ module_id=”stories” _builder_version=”4.16″ _module_preset=”default” custom_padding=”||0px||false|false” da_disable_devices=”off|off|off” global_colors_info=”{}” da_is_popup=”off” da_exit_intent=”off” da_has_close=”on” da_alt_close=”off” da_dark_close=”off” da_not_modal=”on” da_is_singular=”off” da_with_loader=”off” da_has_shadow=”on”][et_pb_row _builder_version=”4.16″ width=”90%” max_width=”2560px” custom_padding=”0px||0px||true|false” global_colors_info=”{}”][et_pb_column type=”4_4″ _builder_version=”4.16″ global_colors_info=”{}”][et_pb_text _builder_version=”4.16″ header_2_font=”|700|||||||” header_2_text_color=”#f7941e” header_2_font_size=”25px” header_2_line_height=”1.2em” global_colors_info=”{}”]<\/p>\n

Stories<\/h2>\n

[\/et_pb_text][\/et_pb_column][\/et_pb_row][et_pb_row _builder_version=”4.16″ _module_preset=”default” custom_css_main_element=”.et-pb-controllers{top:95%!important;bottom:0;}” global_colors_info=”{}”][et_pb_column type=”4_4″ _builder_version=”4.16″ _module_preset=”default” global_colors_info=”{}”][et_pb_slider use_bg_overlay=”off” use_text_overlay=”off” arrows_custom_color=”#000000″ dot_nav_custom_color=”#000000″ _builder_version=”4.16″ _module_preset=”default” header_level=”h3″ header_font=”|700|||||||” header_text_color=”#6398d1″ header_font_size=”20px” body_text_color=”#000000″ body_font_size=”18px” custom_button=”on” button_text_size=”16px” button_text_color=”#ffffff” button_bg_color=”#f7941e” button_border_color=”rgba(0,0,0,0)” width=”100%” module_alignment=”center” custom_padding=”39px||40px|||” global_colors_info=”{}”][et_pb_slide heading=”Sun Pharma is Great Place To Work\u00ae Certified\u2122 in 25 countries” button_text=”Read More” button_link=”https:\/\/dev.sunpharma.com\/sun-pharma-is-great-place-to-work-certified-in-25-countries\/” url_new_window=”on” image=”https:\/\/dev.sunpharma.com\/wp-content\/uploads\/2024\/01\/Banner-copy.jpg” _builder_version=”4.16″ _module_preset=”default” background_color=”#f2f2f2″ background_enable_color=”on” global_colors_info=”{}” sticky_transition=”on”]We are proud to have earned the Great Place To Work\u00ae Certification\u2122 in 25 countries across the globe. The certification was earned by Sun Pharma based on the Trust Index\u2122 Survey by the Great Place To Work\u00ae (GPTW) Institute. Over 38,000 employees participated in the global survey.[\/et_pb_slide][et_pb_slide heading=”Sun Pharma\u2019s Dewas Plant Champions Diversity in Manufacturing” button_text=”Read More” button_link=”https:\/\/dev.sunpharma.com\/sun-pharma-dewas-plant-champions-diversity-in-manufacturing\/” url_new_window=”on” image=”https:\/\/dev.sunpharma.com\/wp-content\/uploads\/2023\/12\/DSC03370-scaled.jpg” _builder_version=”4.16″ _module_preset=”default” background_color=”#f2f2f2″ background_enable_color=”on” global_colors_info=”{}” sticky_transition=”on”]<\/p>\n

In the world of pharmaceutical manufacturing, a domain predominantly associated with men in hard hats and assembly lines, a remarkable transformation has been taking place at Sun\u2019s Dewas plant in India. It\u2019s a tale of breaking the mould and creating a gender diverse team to manage manufacturing blocks.<\/p>\n

[\/et_pb_slide][et_pb_slide heading=”Sun Pharma Recognized as a Great Place to Work in India” button_text=”Read More” button_link=”https:\/\/dev.sunpharma.com\/sun-pharma-is-great-place-to-work-certified-in-india\/” url_new_window=”on” image=”https:\/\/dev.sunpharma.com\/wp-content\/uploads\/2023\/01\/great-place-to-work.jpg” _builder_version=”4.16″ _module_preset=”default” background_color=”#f2f2f2″ background_enable_color=”on” global_colors_info=”{}” sticky_transition=”on”]At Sun Pharma, we believe a great team makes a great workplace, and our employees agree. In October 2022, we became Great Place To Work\u00ae Certified\u2122 in India, and we were also recognized as one of India’s Best Workplaces\u2122 in Pharmaceuticals, Healthcare and Biotech 2022.[\/et_pb_slide][et_pb_slide heading=”Sun Pharma No. 1 Generic Company in PatientView Survey” button_text=”Read More” button_link=”https:\/\/dev.sunpharma.com\/sun-pharma-no-1-generic-company-in-patientview-survey\/” image=”https:\/\/dev.sunpharma.com\/wp-content\/uploads\/2022\/07\/banner-v2.png” _builder_version=”4.16″ _module_preset=”default” background_color=”#f2f2f2″ background_enable_color=”on” global_colors_info=”{}” sticky_transition=”on”]<\/p>\n

At Sun, our patients are at the centre of everything we do. We are committed to helping them lead happier and healthier lives. When we see the difference our work makes in people\u2019s lives, it inspires us to do better.<\/p>\n

[\/et_pb_slide][et_pb_slide heading=”Celebrating 40 Years in Malaysia” button_text=”Read More” button_link=”https:\/\/dev.sunpharma.com\/celebrating-40-years-in-malaysia\/” image=”https:\/\/dev.sunpharma.com\/wp-content\/uploads\/2022\/07\/40-years-malaysia-v3.jpg” _builder_version=”4.16″ _module_preset=”default” background_color=”#f2f2f2″ background_enable_color=”on” global_colors_info=”{}” sticky_transition=”on”]<\/p>\n

This year marks a significant milestone for our team in Malaysia as they celebrate 40 years of successful operations in the country.<\/p>\n

[\/et_pb_slide][\/et_pb_slider][\/et_pb_column][\/et_pb_row][\/et_pb_section][et_pb_section fb_built=”1″ disabled_on=”off|off|off” _builder_version=”4.16″ _module_preset=”default” da_disable_devices=”off|off|off” global_colors_info=”{}” da_is_popup=”off” da_exit_intent=”off” da_has_close=”on” da_alt_close=”off” da_dark_close=”off” da_not_modal=”on” da_is_singular=”off” da_with_loader=”off” da_has_shadow=”on”][et_pb_row _builder_version=”4.16″ width=”90%” max_width=”2560px” custom_padding=”0px||0px||true|false” global_colors_info=”{}”][et_pb_column type=”4_4″ _builder_version=”4.16″ global_colors_info=”{}”][et_pb_text _builder_version=”4.16″ header_2_font=”|700|||||||” header_2_text_color=”#f7941e” header_2_font_size=”25px” header_2_line_height=”1.2em” global_colors_info=”{}”]<\/p>\n

Media Kit<\/h2>\n

[\/et_pb_text][\/et_pb_column][\/et_pb_row][et_pb_row column_structure=”1_2,1_2″ _builder_version=”4.16″ width=”90%” max_width=”2560px” custom_padding=”||0px||false|false” global_colors_info=”{}”][et_pb_column type=”1_2″ _builder_version=”4.16″ global_colors_info=”{}”][et_pb_button button_url=”https:\/\/dev.sunpharma.com\/wp-content\/uploads\/2021\/01\/Sun-Pharma-Brand-Website.pdf” url_new_window=”on” button_text=”Sun Pharma Brand Guidelines” button_alignment=”center” _builder_version=”4.16″ custom_button=”on” button_text_size=”18px” button_text_color=”#ffffff” button_bg_color=”#6398d1″ button_border_width=”0px” global_colors_info=”{}”][\/et_pb_button][\/et_pb_column][et_pb_column type=”1_2″ _builder_version=”4.16″ global_colors_info=”{}”][et_pb_button button_url=”https:\/\/dev.sunpharma.com\/wp-content\/uploads\/2021\/01\/Sun-Pharma-Logos-1.pdf” url_new_window=”on” button_text=”Sun Pharma Logo” button_alignment=”center” _builder_version=”4.16″ custom_button=”on” button_text_size=”18px” button_text_color=”#ffffff” button_bg_color=”#f7941e” button_border_width=”0px” global_colors_info=”{}”][\/et_pb_button][\/et_pb_column][\/et_pb_row][\/et_pb_section][et_pb_section fb_built=”1″ _builder_version=”4.16″ _module_preset=”default” da_disable_devices=”off|off|off” global_colors_info=”{}” da_is_popup=”off” da_exit_intent=”off” da_has_close=”on” da_alt_close=”off” da_dark_close=”off” da_not_modal=”on” da_is_singular=”off” da_with_loader=”off” da_has_shadow=”on”][\/et_pb_section][et_pb_section fb_built=”1″ disabled_on=”on|on|on” _builder_version=”4.16″ _module_preset=”default” da_disable_devices=”off|off|off” disabled=”on” global_colors_info=”{}” da_is_popup=”off” da_exit_intent=”off” da_has_close=”on” da_alt_close=”off” da_dark_close=”off” da_not_modal=”on” da_is_singular=”off” da_with_loader=”off” da_has_shadow=”on”][\/et_pb_section][et_pb_section fb_built=”1″ disabled_on=”on|on|on” _builder_version=”4.16″ _module_preset=”default” da_disable_devices=”off|off|off” disabled=”on” global_colors_info=”{}” da_is_popup=”off” da_exit_intent=”off” da_has_close=”on” da_alt_close=”off” da_dark_close=”off” da_not_modal=”on” da_is_singular=”off” da_with_loader=”off” da_has_shadow=”on”][\/et_pb_section][et_pb_section fb_built=”1″ module_id=”contacts” _builder_version=”4.16″ background_color=”#f2f2f2″ da_disable_devices=”off|off|off” global_colors_info=”{}” da_is_popup=”off” da_exit_intent=”off” da_has_close=”on” da_alt_close=”off” da_dark_close=”off” da_not_modal=”on” da_is_singular=”off” da_with_loader=”off” da_has_shadow=”on”][et_pb_row _builder_version=”4.16″ width=”90%” max_width=”2560px” custom_padding=”0px||0px||true|false” global_colors_info=”{}”][et_pb_column type=”4_4″ _builder_version=”4.16″ global_colors_info=”{}”][et_pb_text _builder_version=”4.16″ header_2_font=”|700|||||||” header_2_text_color=”#f7941e” header_2_font_size=”25px” header_2_line_height=”1.2em” global_colors_info=”{}”]<\/p>\n

Media Contacts<\/h2>\n

[\/et_pb_text][\/et_pb_column][\/et_pb_row][et_pb_row column_structure=”1_2,1_2″ _builder_version=”4.16″ width=”90%” max_width=”2560px” custom_padding=”||0px||false|false” global_colors_info=”{}”][et_pb_column type=”1_2″ _builder_version=”4.16″ global_colors_info=”{}”][et_pb_text _builder_version=”4.16″ text_text_color=”#000000″ text_line_height=”1.8em” header_3_font=”|700|||||||” header_3_text_color=”#6398d1″ header_3_font_size=”20px” header_3_line_height=”1.2em” header_4_font=”|700|||||||” header_4_text_color=”#000000″ header_4_line_height=”1.4em” global_colors_info=”{}”]<\/p>\n

Global Headquarters<\/h3>\n

Mumbai, India<\/h4>\n

Gaurav Chugh<\/p>\n

Global Communications Lead<\/em><\/p>\n

(+91 22) 4324 4324 Extn: 5373<\/p>\n

gaurav.chugh@dev.sunpharma.com<\/a><\/p>\n

[\/et_pb_text][\/et_pb_column][et_pb_column type=”1_2″ _builder_version=”4.16″ _module_preset=”default” global_colors_info=”{}”][\/et_pb_column][\/et_pb_row][\/et_pb_section]<\/p>\n","protected":false},"excerpt":{"rendered":"

Here you will find our latest & archived press releases, stories and our corporate brand guidelines.Press Releases\n\n\n\n\t\n\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t
Press Release<\/th>Date<\/th>\n<\/tr>\n<\/thead>\n
Earnings call for the financial results of the fourth quarter on 22 May 2026
\n<\/a><\/td>		13 May 2026<\/td>\n<\/tr>\n
Investor call to discuss the acquisition of Organon & Co.<\/a><\/td>27 April 2026<\/td>\n<\/tr>\n
Sun Pharma signs Definitive Agreement to Acquire Organon<\/a><\/td>27 April 2026<\/td>\n<\/tr>\n
Sun Pharma Highlights Advances in Alopecia Areata, Psoriasis, and Acne Research at 2026 AAD Annual Meeting<\/a><\/td>27 March 2026<\/td>\n<\/tr>\n
Sun Pharma launches its semaglutide injection under the brand names, Noveltreat and Sematrinity in India Psoriatic Arthritis<\/a><\/td>21 March 2026<\/td>\n<\/tr>\n
Sun Pharma Announces US FDA Acceptance of Supplemental Biologics License (sBLA) Application for ILUMYA\u00ae (tildrakizumab-asmn) for the Treatment of Adults with Active Psoriatic Arthritis <\/a><\/td>March 16, 2026<\/td>\n<\/tr>\n
Sun Pharma Introduces SUNday, Highlighting the Everyday Realities of Skin Cancer Care <\/a><\/td>February 05, 2026<\/td>\n<\/tr>\n
Sun Pharma Comes on Board as Principal Sponsor and Health Partner of Royal Challengers Bengaluru (RCB) for T20 Season 2026 <\/a><\/td>February 04, 2026<\/td>\n<\/tr>\n
Sun Pharma reports Q3FY26 Financial Results<\/a><\/td>January 31, 2026<\/td>\n<\/tr>\n
Sun Pharma receives DCGI approval to manufacture and market generic semaglutide injection in India for chronic weight management<\/a><\/td>January 23, 2026<\/td>\n<\/tr>\n
Earnings call for the financial results of the third quarter on 31 January 2026<\/a><\/td>January 21, 2026<\/td>\n<\/tr>\n
Sun Pharma Announces the Availability of UNLOXCYT\u2122 (cosibelimab-ipdl) for Advanced Cutaneous Squamous Cell Carcinoma (aCSCC)<\/a><\/td>January 15, 2026<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n\n\n\n\n\t\n\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t
Press Release<\/th>Date<\/th>\n<\/tr>\n<\/thead>\n
Sun Pharma introduces its global innovative drug, Ilumya\u00ae in India for treatment of moderate-to-severe Plaque Psoriasis<\/a><\/td>December 1, 2025<\/td>\n<\/tr>\n
FDA approves label update for UNLOXCYT\u2122 (cosibelimab-ipdl) based on longer-term data that demonstrated improved clinical outcomes in advanced cutaneous squamous cell carcinoma (aCSCC)<\/a><\/td>November 26, 2025<\/td>\n<\/tr>\n
AstraZeneca Pharma India Limited and Sun Pharma partner to help patients living with Hyperkalaemia in India<\/a><\/td>November 17, 2025<\/td>\n<\/tr>\n
Sun Pharma launches \u2018#SeeBeyondSugar\u2019 campaign on World Diabetes Day: A nation-wide initiative to raise awareness about Diabetic Retinopathy<\/a><\/td>November 14, 2025<\/td>\n<\/tr>\n
Sun Pharma Presents Two Posters on Utreglutide at ObesityWeek\u00ae 2025<\/a><\/td>November 12, 2025<\/td>\n<\/tr>\n
Sun Pharma Presents Data from Phase 1b\/2a Study of GL0034 at the American Heart Association 2025 Scientific Sessions<\/a><\/td>November 12, 2025<\/td>\n<\/tr>\n
Philogen provides update on Fibromun clinical study developments<\/a><\/td>November 12, 2025<\/td>\n<\/tr>\n
Sun Pharma reports Q2FY26 Financial Results<\/a><\/td>November 05, 2025<\/td>\n<\/tr>\n
Earnings call for the financial results of the second quarter on 05 November 2025<\/a><\/td>October 15, 2025<\/td>\n<\/tr>\n
Sun Pharma reports Q1FY26 Financial Results<\/a><\/td>July 31, 2025<\/td>\n<\/tr>\n
Sun Pharma\u2019s Phase 3 Clinical Studies Evaluating Tildrakizumab 100 mg (ILUMYA) in Active Psoriatic Arthritis Meet their Primary Endpoint<\/a><\/td>July 21, 2025<\/td>\n<\/tr>\n
Sun Pharma to announce first-quarter results on July 31, 2025<\/a><\/td>July 15, 2025<\/td>\n<\/tr>\n
Sun Pharma Announces Launch of LEQSELVI\u2122 (deuruxolitinib) in the United States for the Treatment of Severe Alopecia Areata<\/a><\/td>July 14, 2025<\/td>\n<\/tr>\n
Sun Pharma announces settlement with Incyte Corporation in litigation relating to LEQSELVI\u2122<\/a><\/td>July 14, 2025<\/td>\n<\/tr>\n
Philogen Provides Update on Marketing Authorization Application for Nidlegy\u2122 in the European Union<\/a><\/td>June 24, 2025<\/td>\n<\/tr>\n
Sun Pharma Announces Top-Line Results from the Phase 2 Clinical Trials Evaluating SCD-044 for Moderate to Severe Psoriasis and Atopic Dermatitis<\/a><\/td>June 3, 2025<\/td>\n<\/tr>\n
Sun Pharma appoints Kirti Ganorkar as the Managing Director; Dilip Shanghvi to continue as the Executive Chairman of the Board<\/a><\/td>June 13, 2025<\/td>\n<\/tr>\n
Sun Pharma announces the completion of its acquisition of Checkpoint Therapeutics, Inc.<\/a><\/td>May 30, 2025<\/td>\n<\/tr>\n
Sun Pharma reports Q4 and full year results for FY25<\/a><\/td>May 22, 2025<\/td>\n<\/tr>\n
Sun Pharma to announce fourth-quarter results on May 22, 2025<\/a><\/td>May 12, 2025<\/td>\n<\/tr>\n
Sun Pharma Announces FDA Approval of Next Generation BLU-U\u00ae Blue Light Photodynamic Therapy Illuminator for Actinic Keratosis<\/a><\/td>May 16, 2025<\/td>\n<\/tr>\n
Sun Pharma Launches Corporate Brand Campaign in India
\n<\/a><\/td>		May 8, 2025<\/td>\n<\/tr>\n
Sun Pharma and Moebius Medical Announce Dual Publications on MM-II\u2019s Phase 2b Clinical Trial Results and Mechanism of Action in Osteoarthritis and Cartilage<\/a><\/td>April 24, 2025<\/td>\n<\/tr>\n
Sun Pharma introduces a novel class of drug, Fexuclue\u00ae(Fexuprazan) in India for treatment of Erosive Esophagitis<\/a><\/td>April 07, 2025<\/td>\n<\/tr>\n
Music Icon Art Garfunkel Opens Up About His Experience with Psoriasis in Partnership with Sun Pharma<\/a><\/td>April 04, 2025<\/td>\n<\/tr>\n
Sun Pharma to Acquire Checkpoint Therapeutics<\/a><\/td>March 10, 2025<\/td>\n<\/tr>\n
ILUMYA\u00ae Found Effective for Treatment of Plaque Psoriasis Affecting Nails in Study Presented at 2025 AAD Conference<\/a><\/td>March 7, 2025<\/td>\n<\/tr>\n
Sun Pharma Amongst Top 5% Of Global Pharmaceutical Companies In S&P Global Sustainability Yearbook 2025<\/a><\/td>February 17, 2025<\/td>\n<\/tr>\n
Philogen Completes Patient Enrollment of the Phase III FIBROSARC Trial in Soft Tissue Sarcoma<\/a><\/td>February 04, 2025<\/td>\n<\/tr>\n
Sun Pharma reports Q3 FY25 results<\/a><\/td>January 31, 2025<\/td>\n<\/tr>\n
Sun Pharma to announce third-quarter results on January 31, 2025
\n <\/a><\/td>		January 31, 2025<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n\n\n\n\n\t\n\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t
Press Release<\/th>Date<\/th>\n<\/tr>\n<\/thead>\n
Sun Pharma reports Q2FY25 results<\/a><\/td>Oct 28, 2024<\/td>\n<\/tr>\n
Sun Pharma Presents LEQSELVI at the 2024 Fall Clinical Dermatology Conference<\/a><\/td>Oct 25, 2024<\/td>\n<\/tr>\n
WINLEVI poster presentations at 2024 Fall Clinical Dermatology Conference<\/a><\/td>Oct 25, 2024<\/td>\n<\/tr>\n
Sun Pharma to announce Second quarter results on October 28, 2024<\/a><\/td>Oct 1, 2024<\/td>\n<\/tr>\n
Sun Pharma and Philogen enter into a global Exclusive Commercialization, License, and Supply Agreement for Commercializing the specialty product FIBROMUN<\/a><\/td>Oct 1, 2024<\/td>\n<\/tr>\n
Sun Pharma Presents New Clinical Efficacy and Safety Data in Severe Dermatological Conditions at the 2024 European Academy of Dermatology and Venereology (EADV) Congress<\/a><\/td>Sept 26, 2024<\/td>\n<\/tr>\n
Sun Pharma and Moebius Medical Announce Fast Track Designation Granted for MM-II for the Treatment of Osteoarthritis Knee Pain<\/a><\/td>Sept 06, 2024<\/td>\n<\/tr>\n
Sun Pharma introduces a novel treatment, STARIZO (Tedizolid Phosphate) in India for acute bacterial skin and skin structure infections<\/a><\/td>August 23, 2024<\/td>\n<\/tr>\n
Sun Pharma reports Q1 FY25 Financial Press Release<\/a><\/td>August 01, 2024<\/td>\n<\/tr>\n
U.S. FDA Approves LEQSELVI\u2122 (deuruxolitinib), an Oral JAK Inhibitor for the Treatment of Severe Alopecia Areata<\/a><\/td>July 26, 2024<\/td>\n<\/tr>\n
Sun Pharma to announce first quarter results on August 01, 2024<\/a><\/td>July 16, 2024<\/td>\n<\/tr>\n
Validation of Nidlegy\u2122 Marketing Authorization Application Submission by EMA<\/a><\/td>July 04, 2024<\/td>\n<\/tr>\n
Sun Pharma Launches #SecondBirthDate 2.0 Initiative with Sushmita Sen on National Doctors\u2019 Day: Celebrating Real-life Heroes<\/a><\/td>July 01, 2024<\/td>\n<\/tr>\n
Sun Pharma Completes Taro Merger<\/a><\/td>June 24, 2024<\/td>\n<\/tr>\n
Sun Pharma\u2019s GL0034 (Utreglutide) Demonstrates Significant Weight Loss, Gluco-metabolic and Lipid Lowering Efficacy in Individuals with Obesity in Oral Presentation at the American Diabetes Association 84th Scientific Sessions<\/a><\/td>June 22, 2024<\/td>\n<\/tr>\n
Sun Pharma signs non-exclusive patent licensing agreement with Takeda for introducing Novel Gastrointestinal Drug, Voltapraz (Vonoprazan) in India<\/a><\/td>June 21, 2024<\/td>\n<\/tr>\n
Oral Presentation at EULAR 2024 of Data from Global Phase 2b Clinical Trial Demonstrates Durability of Pain Relief After a Single Injection of MM-II in Patients with Painful Knee Osteoarthritis (OA)<\/a><\/td>June 14, 2024<\/td>\n<\/tr>\n
Press Release Nidlegy\u2122 Marketing Authorization Application Submitted to EMA<\/a><\/td>June 04, 2024<\/td>\n<\/tr>\n
Press Release Results of the Phase III PIVOTAL trial of Nidlegy in melanoma to be presented at ASCO 2024<\/a><\/td>May 31, 2024<\/td>\n<\/tr>\n
Taro Shareholders Approve Merger with Sun Pharma<\/a><\/td>May 23, 2024<\/td>\n<\/tr>\n
Sun Pharma reports Q4 and full year FY24 Financial Press Release<\/a><\/td>May 22, 2024<\/td>\n<\/tr>\n
Sun Pharma to announce fourth quarter results on May 22, 2024<\/a><\/td>May 15, 2024<\/td>\n<\/tr>\n
Sun Pharmaceuticals announces approval of Winlevi\u00ae<\/sup> in Australia<\/a><\/td>March 19, 2024<\/td>\n<\/tr>\n
Sun Pharma included in S&P Global Sustainability Yearbook 2024<\/a><\/td>February 12, 2024<\/td>\n<\/tr>\n
Sun Pharma reports Q3FY24 results<\/a><\/td>January 31, 2024<\/td>\n<\/tr>\n
Taro Announces Merger Agreement with Sun Pharma<\/a><\/td>January 18, 2024<\/td>\n<\/tr>\n
Sun Pharma and Bayer sign marketing and distribution agreement for second brand of Finerenone in India
\n<\/a><\/td>		January 17, 2024<\/td>\n<\/tr>\n
Sun Pharma to announce third quarter results on January 31, 2024<\/a><\/td>January 16, 2024<\/td>\n<\/tr>\n
<\/td><\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n\n\n\n\n\t\n\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t
Press Release<\/th>Date<\/th>\n<\/tr>\n<\/thead>\n
Q2 FY24 Financial Press Release<\/a><\/td>November 1, 2023<\/td>\n<\/tr>\n
Sun Pharma and Zydus sign licensing agreement for co-marketing of Desidustat in India<\/a><\/td>October 30, 2023<\/td>\n<\/tr>\n
Sun Pharma to announce second quarter results on November 01, 2023<\/a><\/td>October 17, 2023<\/td>\n<\/tr>\n
Nidlegy\u2122 Phase III PIVOTAL trial meets the study\u2019s primary objective demonstrating statistically significant and clinically meaningful improvement in Recurrence-Free Survival for patients with locally advanced fully resectable melanoma<\/a><\/td>October 16, 2023<\/td>\n<\/tr>\n
CEQUA\u00ae (cyclosporine ophthalmic solution) 0.09% Phase 4 Data Showed Sustained Improvement in Dry Eye Disease Signs and Symptoms in Patients Switched From Restasis\u00ae (cyclosporine ophthalmic emulsion) 0.05%<\/a><\/td>October 12, 2023<\/td>\n<\/tr>\n
Sun Pharma Announces US FDA Filing Acceptance of New Drug Application For Deuruxolitinib<\/a><\/td>October 6, 2023<\/td>\n<\/tr>\n
Sun Pharma Canada Launches PR <\/sup>WINLEVI\u00ae (clascoterone cream 1% w\/w), a Novel Topical Treatment for Acne<\/a><\/td>September 27, 2023<\/td>\n<\/tr>\n
Sun Pharma and Pharmazz Inc. enter into licensing agreement for introducing Tyvalzi\u2122 (Sovateltide) in India<\/a><\/td>September 14, 2023<\/td>\n<\/tr>\n
Sun Pharma to announce first quarter results on August 03, 2023<\/a><\/td>July 17, 2023<\/td>\n<\/tr>\n
Sun Pharma launches nationwide initiative, #SecondBirthDate on National Doctor\u2019s Day<\/a><\/td>July 1, 2023<\/td>\n<\/tr>\n
ADA GL0034 Data Release<\/a><\/td>June 24, 2023<\/td>\n<\/tr>\n
Sun Pharma Announces Health Canada Approval of PRWINLEVI\u00ae (clascoterone cream 1%) for Topical Treatment of Acne<\/a><\/td>June 19, 2023<\/td>\n<\/tr>\n
Sun Pharma Announces China NMPA Approval For ILUMETRI (Tildrakizumab Injection) For Treatment Of Adults with Moderate-To-Severe Plaque Psoriasis<\/a><\/td>May 30, 2023<\/td>\n<\/tr>\n
Sun Pharma and Philogen enter into an Exclusive Distribution, License, and Supply Agreement for Commercializing specialty product, NIDLEGY\u2122 in Europe, Australia and New Zealand<\/a><\/td>May 30, 2023<\/td>\n<\/tr>\n
Q4 FY23 Financial Press Release<\/a><\/td>May 26, 2023<\/td>\n<\/tr>\n
Sun Pharma to announce fourth quarter results on May 26, 2023<\/a><\/td>May 26, 2023<\/td>\n<\/tr>\n
Sun Pharma launches CEQUA, a novel therapy for Dry Eye Disease in India<\/a><\/td>April 25, 2023<\/td>\n<\/tr>\n
Osteoarthritis Candidate MM-II Showed Durable Pain Relief in Global Phase 2b Study<\/a><\/td>March 22, 2023<\/td>\n<\/tr>\n
Late-Breaking Phase 3 Data at AAD 2023 Show Oral Investigational Medicine Deuruxolitinib Significantly Improved Scalp Hair Regrowth in Alopecia Areata<\/a><\/td>March 18, 2023<\/td>\n<\/tr>\n
Sun Pharma completes acquisition of Concert Pharmaceuticals<\/a><\/td>March 06, 2023<\/td>\n<\/tr>\n
Sun Pharma Announces US FDA Approval for Generic Lenalidomide Capsules<\/a><\/td>February 10, 2023<\/td>\n<\/tr>\n
Q3 FY23 Financial Press Release<\/a><\/td>January 31, 2023<\/td>\n<\/tr>\n
Sun Pharma acquires Disperzyme\u00ae and Phlogam\u00ae brands to strengthen its anti-inflammatory portfolio<\/a><\/td>January 30, 2023<\/td>\n<\/tr>\n
Sun Pharma Launches SEZABY\u2122 (phenobarbital sodium) in the U.S. for Treatment of Neonatal Seizures<\/a><\/td>January 25, 2023<\/td>\n<\/tr>\n
Sun Pharma to Acquire Concert Pharmaceuticals Inc<\/a<\/td>January 19, 2023<\/td>\n<\/tr>\n
Sun Pharma to announce third quarter results on January 31, 2023<\/a><\/td>January 17, 2023<\/td>\n<\/tr>\n
Sun Pharma launches Palbociclib, a novel targeted therapy for advanced breast cancer with a unique Patient Assistance Program<\/a><\/td>January 11, 2023<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n\n\n\n\n\t\n\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t
Press Release <\/th>Date<\/th>\n<\/tr>\n<\/thead>\n
Sun Pharma is Great Place To Work\u00ae Certified\u2122 in India<\/a><\/td>December 21, 2022<\/td>\n<\/tr>\n
SEZABY\u2122 (phenobarbital sodium powder for injection) approved by US FDA for the treatment of neonatal seizures<\/a><\/td>November 18, 2022<\/td>\n<\/tr>\n
Sun Pharma and SPARC enter into a license agreement for commercialization of phenobarbital for injection in the US<\/a><\/td>November 09, 2022<\/td>\n<\/tr>\n
Q2 FY23 Financial Press Release<\/a><\/td>November 01, 2022<\/td>\n<\/tr>\n
\u201cApni Body Ki Suno\u201d says the latest campaign of Sun Pharma\u2019s Revital H<\/a><\/td>October 14, 2022<\/td>\n<\/tr>\n
Sun Pharma to announce second quarter results on November 01, 2022<\/a>
\n<\/td>		October 11, 2022<\/td>\n<\/tr>\n
Sun Pharma Chairman, Israel Makov to retire on completion of term<\/a><\/td>August 03, 2022<\/td>\n<\/tr>\n
Sun Pharma and Cosmo Announce Territory Expansion of License and Supply Agreements for WINLEVI\u00ae to include Japan, Australia, New Zealand, Brazil, Mexico and Russia<\/a><\/td>July 26, 2022<\/td>\n<\/tr>\n
Sun Pharma to announce first quarter results on July 29, 2022<\/a><\/td>July 13, 2022<\/td>\n<\/tr>\n
Q4 FY22 Financial Press Release<\/a><\/td>May 30, 2022<\/td>\n<\/tr>\n
Sun Pharma Acquires Uractiv\u2122 Portfolio from Fiterman Pharma in Romania<\/a><\/td>May 27, 2022<\/td>\n<\/tr>\n
Sun Pharma to launch Brillo\u00ae, a first-in-class oral lipid-lowering drug in India<\/a><\/td>May 18, 2022<\/td>\n<\/tr>\n
Sun Pharma to announce fourth quarter results on May 30, 2022<\/a><\/td>May 16, 2022<\/td>\n<\/tr>\n
Sun Pharma Announces US FDA Approval for Generic Mesalamine Extended Release Capsules<\/a><\/td>May 12, 2022<\/td>\n<\/tr>\n
Sun Pharma to introduce its version of Vortioxetine in India under an exclusive patent license from Lundbeck<\/a><\/td>March 30, 2022<\/td>\n<\/tr>\n
Intimation under Regulation 30- 29th March, 2022<\/a><\/td>March 29, 2022<\/td>\n<\/tr>\n
Sun Pharma Presents Phase 3 Data for WINLEVI\u00ae (clascoterone) cream 1% for the Topical Treatment of Acne Vulgaris at the AAD Annual Meeting<\/a><\/td>March 25, 2022<\/td>\n<\/tr>\n
Q3 FY22 Financial Press Release<\/a><\/td>January 31, 2022<\/td>\n<\/tr>\n
Sun Pharma launches CEQUA\u2122 (cyclosporine ophthalmic solution 0.09% w\/v), the first dry eye treatment with nanomicellar (NCELL\u2122) technology*, in Canada<\/a><\/td>January 27, 2022<\/td>\n<\/tr>\n
Sun Pharma to announce third quarter results on January 31, 2022<\/a><\/td>January 18, 2022<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n\n\n\n\n\t\n\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t
Press Release<\/th>Date<\/th>\n<\/tr>\n<\/thead>\n
Sun Pharma receives DCGI approval for Molxvir\u00ae (Molnupiravir) in India<\/a><\/td>December 28, 2021<\/td>\n<\/tr>\n
Sun Pharma Announces US FDA Approval for Generic Amphotericin B Liposome Injection<\/a><\/td>December 15, 2021<\/td>\n<\/tr>\n
Sun Pharma geared to introduce Molnupiravir, licensed from MSD and Ridgeback, under the brand name Molxvir\u00ae in India<\/a><\/td>November 11, 2021<\/td>\n<\/tr>\n
Q2 FY22 Financial Press Release<\/a><\/td>November 2, 2021<\/td>\n<\/tr>\n
Sun Pharma Announces Availability of WINLEVI\u00ae (clascoterone) cream 1% in the U.S. for Topical Treatment of Acne Vulgaris<\/a><\/td>November 1, 2021<\/td>\n<\/tr>\n
Sun Pharma\u2019s ILUMYA\u2122 (tildrakizumab injection) now available to help Canadians living with moderate-to-severe plaque psoriasis<\/a><\/td>October 28, 2021<\/td>\n<\/tr>\n
Sun Pharma to announce second quarter results on November 02, 2021<\/a><\/td>October 19, 2021<\/td>\n<\/tr>\n
Sun Pharma launches Chericof\u00ae 12 in India, a novel formulation that provides relief from cough for up to 12 hours<\/a><\/td>September 28, 2021<\/td>\n<\/tr>\n
Sun Pharma forays into Nutrition Bar segment with the launch of Revital NXT<\/a><\/td>September 08, 2021<\/td>\n<\/tr>\n
Sun Pharma and Cassiopea announce the expiry of the HSR Act process and the successful consummation of their Winlevi\u00ae (clascoterone cream 1%) agreement<\/a><\/td>August 31, 2021<\/td>\n<\/tr>\n
Q1 FY22 Financial Press Release<\/a><\/td>July 30, 2021<\/td>\n<\/tr>\n
Sun Pharma and Cassiopea SpA Announce Signing of License and Supply Agreements for Winlevi\u00ae (clascoterone cream 1%) in US and Canada<\/a><\/td>July 26, 2021<\/td>\n<\/tr>\n
Sun Pharma to announce first quarter results on July 30, 2021<\/a><\/td>July 16, 2021<\/td>\n<\/tr>\n
Sun Pharma launches \u2018Sunkalp\u2019 on the occasion of National Doctors\u2019 Day<\/a><\/td>July 01, 2021<\/td>\n<\/tr>\n
Press Release Pharma Majors Collaborate for Clinical Trial of Anti Viral Drug Molnupiravir for COVID-19<\/a><\/td>June 29, 2021<\/td>\n<\/tr>\n
Press Release Settlement of Patent Litigation for Generic Revlimid in US<\/a><\/td>June 22, 2021<\/td>\n<\/tr>\n
Sun Pharma and Ferring Pharmaceuticals enter into licensing agreement for introducing CARITEC\u00ae in India<\/a><\/td>June 02, 2021<\/td>\n<\/tr>\n
Q4 FY21 Financial Press Release<\/a><\/td>May 27, 2021<\/td>\n<\/tr>\n
Sun Pharma Q4 FY21 financial result on May 27, 2021<\/a><\/td>May 12, 2021<\/td>\n<\/tr>\n
Sun Pharma signs voluntary licensing agreement with Eli Lilly for expanding access to Baricitinib to help alleviate the burden of Covid-19 in India<\/a><\/td>May 10, 2021<\/td>\n<\/tr>\n
Sun Pharma Launches Website for its Long Term Care Portfolio in the US<\/a><\/td>February 25, 2021<\/td>\n<\/tr>\n
Sun Pharma to introduce complete range of Brivaracetam at an affordable price for epilepsy treatment in India<\/a><\/td>February 23, 2021<\/td>\n<\/tr>\n
SPIL Q3FY21 Financials Results<\/a><\/td>January 29, 2021<\/td>\n<\/tr>\n
Sun Pharma\u2019s financials for Q3 and nine month period ending December 31, 2020<\/a><\/td>January 29, 2021<\/td>\n<\/tr>\n
Sun Pharma to announce third quarter results on January 29, 2021<\/a><\/td>January 04, 2021<\/td>\n<\/tr>\n
Sun Pharma announces initiation of Phase 2 Clinical Trial of SCD-044 in Patients with Moderate to Severe Plaque Psoriasis<\/a><\/td>January 04, 2021<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n\n\n\n\n\t\n\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t
Press Release<\/th>Date<\/th>\n<\/tr>\n<\/thead>\n
FY21 Q2 Financial Press Release<\/a><\/td>November 03, 2020<\/td>\n<\/tr>\n
FY21 Q2 Financial Results<\/a><\/td>November 03, 2020<\/td>\n<\/tr>\n
Sun Pharma Announces 5-Year Sustained Efficacy and Safety Results for ILUMYA\u00ae in Patients with Moderate-to-Severe Plaque Psoriasis<\/a><\/td>October 31, 2020<\/td>\n<\/tr>\n
Sun Pharma to announce Second quarter results on November 03, 2020<\/a><\/td>October 22, 2020<\/td>\n<\/tr>\n
Press Release Sun Pharma announces the launch of ILUMYA for treatment of plaque psoriasis in Japan<\/a><\/td>September 23, 2020<\/td>\n<\/tr>\n
FY21 Q1 Financial Result - Transcript<\/a><\/td>August 26, 2020<\/td>\n<\/tr>\n
Sun Pharma launches FluGuard\u00ae (Favipiravir) in India at Rs. 35 per tablet<\/a><\/td>August 04, 2020<\/td>\n<\/tr>\n
FY21 Q1 Financial Press Release<\/a><\/td>July 31, 2020<\/td>\n<\/tr>\n
FY21 Q1 Financial Results<\/a><\/td>July 31, 2020<\/td>\n<\/tr>\n
Sun Pharma launches \u2018Thank you Doctor\u2019 campaign<\/a><\/td>July 09, 2020<\/td>\n<\/tr>\n
FY20 Q4 Financial Result - Transcript<\/a><\/td>July 06, 2020<\/td>\n<\/tr>\n
Sun Pharma announces Japan MHLW approval of ILUMYA for the treatment of Plaque Psoriasis<\/a><\/td>June 29, 2020<\/td>\n<\/tr>\n
Sun Pharma Announces Pre-Clinical Data on GL0034<\/a><\/td>June 24, 2020<\/td>\n<\/tr>\n
Sun Pharma and Hikma enter into exclusive licensing agreement for ILUMYA\u2122 for Middle East & North Africa regions<\/a><\/td>June 15, 2020<\/td>\n<\/tr>\n
Sun Pharma Announces Long-term Insights into the Clinical Use of ILUMYA TM<\/a><\/td>June 13, 2020<\/td>\n<\/tr>\n
Sun Pharma Presents ODOMZO\u00ae and LEVULAN\u00ae KERASTICK\u00ae + BLU-U\u00ae Data, Offering Clinical Insights for Treating People with or at Risk of Skin Cancer<\/a><\/td>June 13, 2020<\/td>\n<\/tr>\n
Sun Pharma initiates Phase II clinical trial on AQCH, a phytopharmaceutical drug, as potential treatment for COVID-19 patients<\/a><\/td>June 05, 2020<\/td>\n<\/tr>\n
Sun Pharma receives approval from DCGI to initiate clinical trial with Nafamostat in Covid 19 patients<\/a><\/td>May 29, 2020<\/td>\n<\/tr>\n
Sun Pharma and SPARC enter into a worldwide license agreement for SCD 044<\/a><\/td>May 28, 2020<\/td>\n<\/tr>\n
Sun Pharma Q4FY20 Financial Results<\/a><\/td>May 27, 2020<\/td>\n<\/tr>\n
FY20 Q4 Financial Press Release<\/a><\/td>May 27, 2020<\/td>\n<\/tr>\n
FY20 Q4 Financial Results<\/a><\/td>May 27, 2020<\/td>\n<\/tr>\n
Sun Pharma to announce fourth quarter results on May 27, 2020<\/a><\/td>May 19, 2020<\/td>\n<\/tr>\n
FY20 Q3 Financial Result - Transcript<\/a><\/td>April 09, 2020<\/td>\n<\/tr>\n
Sun Pharma Commits Donation of Medicines and Hand Sanitizers to Support India\u2019s COVID-19 Pandemic Response<\/a><\/td>March 27, 2020<\/td>\n<\/tr>\n
SPII Donates 2.5 Million Hydroxychloroquine Sulfate Tablets in the U.S. For Potential COVID-19 Treatment<\/a><\/td>March 27, 2020<\/td>\n<\/tr>\n
FY20 Q3 Financial Results<\/a><\/td>February 06, 2020<\/td>\n<\/tr>\n
FY20 Q3 Financial Press Release<\/a><\/td>February 06, 2020<\/td>\n<\/tr>\n
Sun Pharma Introduces ABSORICA LD\u2122 Capsules for Management of Severe Recalcitrant Nodular Acne in the U.S.<\/a><\/td>February 04, 2020<\/td>\n<\/tr>\n
Sun Pharma to announce third quarter results on 06 February 2020<\/a><\/td>January 20, 2020<\/td>\n<\/tr>\n
Sun Pharma and Rockwell Medical enter into licensing agreement for Triferic in India<\/a><\/td>January 15, 2020<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n\n\n\n\n\t\n\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t
Press Release<\/th>Date<\/th>\n<\/tr>\n<\/thead>\n
FY20 Q2 Financial Result - Transcript<\/a><\/td>December 10, 2019<\/td>\n<\/tr>\n
FY20 Q2 Financial Results<\/a><\/td>November 07, 2019<\/td>\n<\/tr>\n
FY20 Q2 Financial Press Release<\/a><\/td>November 07, 2019<\/td>\n<\/tr>\n
Sun Pharma and AstraZeneca enter into License Agreement for Novel Oncology products in China<\/a><\/td>November 06, 2019<\/td>\n<\/tr>\n
Sun Pharma to announce second quarter results on 07 November 2019<\/a><\/td>October 24, 2019<\/td>\n<\/tr>\n
Sun Pharma Launches Drizalma Sprinkle in the US<\/a><\/td>October 16, 2019<\/td>\n<\/tr>\n
Sun Pharma Launches CEQUA for the Treatment of Dry Eye Disease in the US<\/a><\/td>October 14, 2019<\/td>\n<\/tr>\n
Malaria Elimination Programme Receives Mahatma Award for Social Good<\/a><\/td>October 10, 2019<\/td>\n<\/tr>\n
Sun Pharma Presents Long-term Study Results that Show Significant Skin Clearance with ILUMYA<\/a><\/td>October 09, 2019<\/td>\n<\/tr>\n
FY20 Q1 Financial Result - Transcript<\/a><\/td>October 03, 2019<\/td>\n<\/tr>\n
Sun Pharma and China Medical System Holdings Enter into Licensing Agreement for Generic Products in Mainland China<\/a><\/td>August 16, 2019<\/td>\n<\/tr>\n
Sun Pharma and China Medical System Holdings Enter into Licensing Agreement for Generic Products in Mainland ChinaSun Pharma Announces Licensing Agreement With CSIR-IICT<\/a><\/td>August 14, 2019<\/td>\n<\/tr>\n
FY20 Q1 Financial Results<\/a><\/td>August 13, 2019<\/td>\n<\/tr>\n
FY20 Q1 Financial Press Release<\/a><\/td>August 13, 2019<\/td>\n<\/tr>\n
Sun Pharma to announce first quarter results on August 13, 2019<\/a><\/td>August 05, 2019<\/td>\n<\/tr>\n
Sun Pharma Announces Regulatory Filing of Tildrakizumab in Japan<\/a><\/td>August 01, 2019<\/td>\n<\/tr>\n
Sun Pharma Launches Ezallor Sprinkle (Rosuvastatin) in the U.S. for People Who Have Difficulty Swallowing<\/a><\/td>July 15, 2019<\/td>\n<\/tr>\n
Sun Pharma and China Medical System Holdings enter into a License Agreement for Tildrakizumab in Greater China<\/a><\/td>June 27, 2019<\/td>\n<\/tr>\n
Sun Pharma and China Medical System Holdings enter into a License Agreement for Cyclosporine A eye drops in Greater China<\/a><\/td>June 27, 2019<\/td>\n<\/tr>\n
Late Breaking Phase 2 Data Showing Potential of ILUMYA for Psoriatic Arthritis<\/a><\/td>June 14, 2019<\/td>\n<\/tr>\n
FY19 Q4 Financial Results<\/a><\/td>May 28, 2019<\/td>\n<\/tr>\n
FY19 Q4 Financial Press Release<\/a><\/td>May 28, 2019<\/td>\n<\/tr>\n
Sun Pharma to announce fourth quarter results on May 28, 2019<\/a><\/td>May 14, 2019<\/td>\n<\/tr>\n
Sun Pharma Launches Ready-to-Infuse INFUGEM in the U.S.<\/a><\/td>April 08, 2019<\/td>\n<\/tr>\n
FY19 Q3 Financial Result - Transcript<\/a><\/td>March 08, 2019<\/td>\n<\/tr>\n
ILUMYA 3 Year Data Demonstrates Sustained Skin Clearance in Patients with Moderate to Severe Plaque Psoriasis<\/a><\/td>March 01, 2019<\/td>\n<\/tr>\n
FY19 Q3 Financial Press Release<\/a><\/td>February 12, 2019<\/td>\n<\/tr>\n
Sun Pharma Q3 FY19 financial result on 12 February 2019<\/a><\/td>January 28, 2019<\/td>\n<\/tr>\n
Press Release Sun Pharma Investor Update<\/a><\/td>January 22, 2019<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n\n\n\n\n\t\n\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t
Press Release<\/th>Date<\/th>\n<\/tr>\n<\/thead>\n
Investor Update Call Transcript<\/a><\/td>December 27, 2018<\/td>\n<\/tr>\n
DUSA Pharmaceuticals, Inc. Awarded Preliminary Injunctive Relief Prohibiting Biofrontera From Using Its Trade Secrets<\/a><\/td>December 26, 2018<\/td>\n<\/tr>\n
Clarification on recent media reports<\/a><\/td>December 03, 2018<\/td>\n<\/tr>\n
Sun Pharma Announces US FDA Approval For Generic Ganirelix Acetate Injection<\/a><\/td>December 03, 2018<\/td>\n<\/tr>\n
Sun Pharma to hold an Investor Update Call on 03 December 2018<\/a><\/td>December 03, 2018<\/td>\n<\/tr>\n
Sun Pharma to acquire Pola Pharma in Japan<\/a><\/td>November 26, 2018<\/td>\n<\/tr>\n
FY19 Q2 Financial Result - Transcript<\/a><\/td>November 20, 2018<\/td>\n<\/tr>\n
FY19 Q2 Financial Press Release<\/a><\/td>November 13, 2018<\/td>\n<\/tr>\n
Sun Pharma Announces the Availability of ILUMYA in the United States<\/a><\/td>October 23, 2018<\/td>\n<\/tr>\n
Sun Pharma to announce second quarter results on 13 November 2018<\/a><\/td>October 23, 2018<\/td>\n<\/tr>\n
Sun Pharma announces Australian TGA approval of ILUMYA<\/a><\/td>September 21, 2018<\/td>\n<\/tr>\n
Sun Pharma Announces Receipt of European Commission Approval For ILUMETRI<\/a><\/td>September 18, 2018<\/td>\n<\/tr>\n
Sun Pharma and SPARC Announce US FDA Approval of XELPROS<\/a><\/td>September 14, 2018<\/td>\n<\/tr>\n
Clarification to Stock Exchanges on Mohali facility<\/a><\/td>September 11, 2018<\/td>\n<\/tr>\n
Clarification to Stock Exchanges on news regarding Halol facility<\/a><\/td>September 07, 2018<\/td>\n<\/tr>\n
FY19 Q1 Financial Result - Transcript<\/a><\/td>September 04, 2018<\/td>\n<\/tr>\n
Sun Pharma launches Volini Maxx, India\u2019s Strongest Pain Relief Spray<\/a><\/td>August 29, 2018<\/td>\n<\/tr>\n
Sun Pharma Announces USFDA Approval of CEQUA to Treat Dry Eye Disease<\/a><\/td>August 16, 2018<\/td>\n<\/tr>\n
FY19 Q1 Financial Press Release<\/a><\/td>August 14, 2018<\/td>\n<\/tr>\n
Sun Pharma Launches Novel Drug Kapspargo Sprinkle\u2122 in USA<\/a><\/td>August 06, 2018<\/td>\n<\/tr>\n
Sun Pharma to announce first quarter results on 14 August 2018<\/a><\/td>July 27, 2018<\/td>\n<\/tr>\n
Sun Pharma Announces Launch of Generic Glumetza\u00ae Tablets in US<\/a><\/td>July 25, 2018<\/td>\n<\/tr>\n
Sun Pharma Announces USFDA Approval of INFUGEM Injection<\/a><\/td>July 18, 2018<\/td>\n<\/tr>\n
DUSA Pharmaceuticals, Inc. files lawsuit against Biofrontera Inc.<\/a><\/td>July 11, 2018<\/td>\n<\/tr>\n
Sun Pharma signs Akshay Kumar as Revital H Brand Ambassador<\/a><\/td>July 09, 2018<\/td>\n<\/tr>\n
Sun Pharma receives EIR for Halol facility<\/a><\/td>June 12, 2018<\/td>\n<\/tr>\n
Clarification on news regarding Halol<\/a><\/td>June 08, 2018<\/td>\n<\/tr>\n
FY18 Q4 Financial Result - Transcript<\/a><\/td>June 08, 2018<\/td>\n<\/tr>\n
FY18 Q4 Financial Press Release<\/a><\/td>May 25, 2018<\/td>\n<\/tr>\n
Sun Pharma Announces USFDA Approval of YONSA<\/a><\/td>May 23, 2018<\/td>\n<\/tr>\n
Sun Pharma Announces US Launch of Authorized Generic for Welchol Tablets<\/a><\/td>May 17, 2018<\/td>\n<\/tr>\n
Sun Pharma to announce fourth quarter results on 25 May 2018<\/a><\/td>May 11, 2018<\/td>\n<\/tr>\n
Sun Pharma CHC enters anti fungal powder OTC category with ABZORB<\/a><\/td>April 30, 2018<\/td>\n<\/tr>\n
FDEC First Year Report of Malaria Elimination Demonstration Project (MEDP)<\/a><\/td>March 23, 2018<\/td>\n<\/tr>\n
Sun Pharma Announces U.S. FDA Approval of ILUMYA\u2122 (tildrakizumab-asmn)<\/a><\/td>March 21, 2018<\/td>\n<\/tr>\n
ILUMYA\u2122 U.S. Prescribing Information<\/a><\/td>March 21, 2018<\/td>\n<\/tr>\n
ILUMYA\u2122 U.S. Medication Guide<\/a><\/td>March 21, 2018<\/td>\n<\/tr>\n
FY18 Q3 Financial Press Release<\/a><\/td>February 14, 2018<\/td>\n<\/tr>\n
Sun Pharma Science Foundation's Annual Conference and Research Awards Presentation Ceremony<\/a><\/td>February 13, 2018<\/td>\n<\/tr>\n
Sun Pharma to announce third quarter results on February 14, 2018<\/a><\/td>February 02, 2018<\/td>\n<\/tr>\n
Sun Pharma Announces Settlement of Patent Litigation for Generic Linzess in US<\/a><\/td>January 16, 2018<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n\n\n\n\n\t\n\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t
Press Release<\/th>Date<\/th>\n<\/tr>\n<\/thead>\n
Sun Pharma Announces US FDA Acceptance of NDA for OTX-101<\/a><\/td>December 27, 2017<\/td>\n<\/tr>\n
FY18 Q2 Financial Result - Transcript<\/a><\/td>December 02, 2017<\/td>\n<\/tr>\n
Sun Pharmaceutical Industries Inc. Issues Voluntary Nationwide Recall of Riomet\u00ae<\/a><\/td>November 24, 2017<\/td>\n<\/tr>\n
FY18 Q2 Financial Press Release<\/a><\/td>November 14, 2017<\/td>\n<\/tr>\n
Sun Pharma to announce second quarter results on November 14, 2017<\/a><\/td>October 31, 2017<\/td>\n<\/tr>\n
Sun Pharma announces US FDA approval for generic Coreg CR\u00ae<\/a><\/td>October 26, 2017<\/td>\n<\/tr>\n
Sun Pharma Odomzo\u00ae (Sonidegib) New Label Approval<\/a><\/td>September 20, 2017<\/td>\n<\/tr>\n
FY18 Q1 Financial Result - Transcript<\/a><\/td>September 15, 2017<\/td>\n<\/tr>\n
FY18 Q1 Financial Press Release<\/a><\/td>August 11, 2017<\/td>\n<\/tr>\n
Sun Pharma to announce first quarter results on August 11, 2017<\/a><\/td>July 26, 2017<\/td>\n<\/tr>\n
Sun Pharma and Samsung BioLogics announce strategic manufacturing tie up for Tildrakizumab<\/a><\/td>July 04, 2017<\/td>\n<\/tr>\n
Sun Pharma and NIV sign agreement to fight Zika, Chikungunya and Dengue<\/a><\/td>June 27, 2017<\/td>\n<\/tr>\n
US FDA approval for generic Zetia\u00ae tablets<\/a><\/td>June 13, 2017<\/td>\n<\/tr>\n
FY17 Q4 Financial Result - Transcript<\/a><\/td>June 13, 2017<\/td>\n<\/tr>\n
FY17 Q4 Financial Press Release<\/a><\/td>May 26, 2017<\/td>\n<\/tr>\n
US FDA Filing Acceptance of Biologics License Application For Tildrakizumab<\/a><\/td>May 24, 2017<\/td>\n<\/tr>\n
Sun Pharma to announce fourth quarter results on May 26, 2017<\/a><\/td>May 15, 2017<\/td>\n<\/tr>\n
Sun Pharma Science Foundation recognizes Indian scientists & young research scholars<\/a><\/td>April 28, 2017<\/td>\n<\/tr>\n
FDEC commences roll-out of Malaria demonstration project<\/a><\/td>April 25, 2017<\/td>\n<\/tr>\n
Sun Pharma Science Foundation Media Invitation<\/a><\/td>April 25, 2017<\/td>\n<\/tr>\n
Almirall and Sun Pharma Announce Regulatory Filing of Tildrakizumab in Europe<\/a><\/td>March 24, 2017<\/td>\n<\/tr>\n
Update on Mohali Facility<\/a><\/td>March 14, 2017<\/td>\n<\/tr>\n
Tildrakizumab Clinical Development Program to be Presented at the 2017 American Academy of Dermatology Meeting<\/a><\/td>March 01, 2017<\/td>\n<\/tr>\n
FY17 Q3 Financial Result - Transcript<\/a><\/td>February 27, 2017<\/td>\n<\/tr>\n
FY17 Q3 Financial Press Release<\/a><\/td>February 14, 2017<\/td>\n<\/tr>\n
Sun Pharma Q3 FY17 financial result on February 14, 2017<\/a><\/td>January 31, 2017<\/td>\n<\/tr>\n
Sun Pharma Announces Positive Topline Results of Confirmatory Phase-3 Clinical Trial for Seciera\u2122 for Treatment of Dry Eye<\/a><\/td>January 04, 2017<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n\n\n\n\n\t\n\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t
Press Release<\/th>Date<\/th>\n<\/tr>\n<\/thead>\n
Sun Pharma & Moebius Medical sign deal to develop novel liposomal non-opiod pain product for osteoarthritis<\/a><\/td>December 12, 2016<\/td>\n<\/tr>\n
FY17 Q2 Financial Result - Transcript<\/a><\/td>November 30, 2016<\/td>\n<\/tr>\n
Sun Pharma launches first branded ophthalmic product, BromSite in USA<\/a><\/td>November 28, 2016<\/td>\n<\/tr>\n
Sun Pharma to acquire Biosintez in Russia<\/a><\/td>November 23, 2016<\/td>\n<\/tr>\n
ICMR, Govt of MP and FDEC-India sign tri-party agreement to launch Malaria Free India demonstration project in Mandla district of Madhya Pradesh- English Press Release<\/a><\/td>November 15, 2016
\n<\/td>\n<\/tr>\n
ICMR, Govt of MP and FDEC-India sign tri-party agreement to launch Malaria Free India demonstration project in Mandla district of Madhya Pradesh- Hindi Press Release<\/a><\/td>November 15, 2016
\n<\/td>\n<\/tr>\n
FY17 Q2 Financial Press Release<\/a><\/td>November 10, 2016<\/td>\n<\/tr>\n
Sun Pharma Announces US Launch of Authorized Generics for Olmesartan<\/a><\/td>October 27, 2016<\/td>\n<\/tr>\n
Sun Pharma Q2 FY17 financial result on November 10, 2016<\/a><\/td>October 26, 2016<\/td>\n<\/tr>\n
Sun Pharma to Acquire Ocular Technologies<\/a><\/td>October 26, 2016<\/td>\n<\/tr>\n
Sun Pharma & ICGEB announce new exclusive collaboration to develop novel dengue vaccine for India & Global markets<\/a><\/td>October 19, 2016<\/td>\n<\/tr>\n
Revital H Woman launches \u2018Healthy Conversations\u2019 initiative<\/a><\/td>October 03, 2016<\/td>\n<\/tr>\n
Sun Pharma to Announce Late-Breaking Results for Tildrakizumab<\/a><\/td>October 01, 2016<\/td>\n<\/tr>\n
Sun Pharma announces distribution alliance with Mitsubishi Tanabe Pharma Corporation in Japan<\/a><\/td>September 06, 2016<\/td>\n<\/tr>\n
FY17 Q1 Financial Result - Transcript<\/a><\/td>August 29, 2016<\/td>\n<\/tr>\n
FY17 Q1 Financial Press Release<\/a><\/td>August 12, 2016<\/td>\n<\/tr>\n
Sun Pharma extends Imatinib Mesylate Savings Card program benefits for patients in USA<\/a><\/td>August 08, 2016<\/td>\n<\/tr>\n
Sun Pharma announces US FDA approval for generic Glumetza\u00ae<\/a><\/td>August 02, 2016<\/td>\n<\/tr>\n
Sun Pharma to announce first quarter results on August 12, 2016<\/a><\/td>August 01, 2016<\/td>\n<\/tr>\n
Sun Pharma and Almirall enter into a License Agreement for Tildrakizumab in Europe for Psoriasis<\/a><\/td>July 27, 2016<\/td>\n<\/tr>\n
Sun Pharma announces US FDA approval for generic Crestor\u00ae<\/a><\/td>July 20, 2016<\/td>\n<\/tr>\n
SPARC licenses Elepsia XR to Sun Pharma<\/a><\/td>July 18, 2016<\/td>\n<\/tr>\n
Sun Pharma launches Gemcitabine InfuSMART<\/a><\/td>July 11, 2016<\/td>\n<\/tr>\n
Sun Pharma Announces Buyback of Equity Shares<\/a><\/td>June 23, 2016<\/td>\n<\/tr>\n
FY16 Q4 Financial Result - Transcript<\/a><\/td>June 10, 2016<\/td>\n<\/tr>\n
Sun Pharma focuses on dermatology as additional engine of growth for GCH business-Press Release<\/a><\/td>June 08, 2016<\/td>\n<\/tr>\n
Sun Pharma focuses on dermatology as additional engine of growth for GCH business-Factsheet<\/a><\/td>June 08, 2016<\/td>\n<\/tr>\n
Press Conference Invitation<\/a><\/td>June 06, 2016<\/td>\n<\/tr>\n
Sun Pharma announces divestment of US manufacturing units<\/a><\/td>June 04, 2016<\/td>\n<\/tr>\n
FY16 Q4 Financial Press Release<\/a><\/td>May 30, 2016<\/td>\n<\/tr>\n
Sun Pharma to announce fourth quarter results on May 30, 2016<\/a><\/td>May 19, 2016<\/td>\n<\/tr>\n
Sun Pharma leverages mobile technology to boost treatment compliance amongst asthma patients<\/a><\/td>May 09, 2016<\/td>\n<\/tr>\n
Sun Pharma Announces Positive Results of Two Pivotal Phase-3 Clinical Trials of Tildrakizumab in Patients with Moderate-to-Severe Plaque Psoriasis<\/a><\/td>May 04, 2016<\/td>\n<\/tr>\n
ICGEB & Sun Pharma sign an exclusive agreement to develop novel botanical drug for treatment of Dengue<\/a><\/td>May 04, 2016<\/td>\n<\/tr>\n
ICGEB & Sun Pharma sign an exclusive agreement to develop novel botanical drug for treatment of Dengue - Endorsements <\/a><\/td>May 04, 2016<\/td>\n<\/tr>\n
ICGEB & Sun Pharma sign an exclusive agreement to develop novel botanical drug for treatment of Dengue -Dengue Factsheet <\/a><\/td>May 04, 2016<\/td>\n<\/tr>\n
Media Invitation - Signing of Novel Drug Development Agreement, May 4, 2016 <\/a><\/td>April 29, 2016<\/td>\n<\/tr>\n
ICMR, MoHFW, GoI, GoMP and Sun Pharma announce Public-Private-Partnership for Malaria Free India - Press Release- Malaria Free India <\/a><\/td>April 25, 2016<\/td>\n<\/tr>\n
ICMR, MoHFW, GoI, GoMP and Sun Pharma announce Public-Private-Partnership for Malaria Free India - Malaria Free India public-private-partnership receives global recognition<\/a><\/td>April 25, 2016<\/td>\n<\/tr>\n
ICMR, MoHFW, GoI, GoMP and Sun Pharma announce Public-Private-Partnership for Malaria Free India - Malaria Free India Blue Print<\/a><\/td>April 25, 2016<\/td>\n<\/tr>\n
ICMR, MoHFW, GoI, GoMP and Sun Pharma announce Public-Private-Partnership for Malaria Free India - Malaria Factsheet<\/a><\/td>April 25, 2016<\/td>\n<\/tr>\n
ICMR, MoHFW, GoI, GoMP and Sun Pharma announce Public-Private-Partnership for Malaria Free India - Spokesperson Bios<\/a><\/td>April 25, 2016<\/td>\n<\/tr>\n
Press Conference Invitation, April 25, New Delhi<\/a><\/td>April 21, 2016<\/td>\n<\/tr>\n
Sun Pharma Receives USFDA Approval For BromSite\u2122<\/a><\/td>April 09, 2016<\/td>\n<\/tr>\n
Sun Pharma enters Japanese prescription market<\/a><\/td>March 29, 2016<\/td>\n<\/tr>\n
Sun Pharma and AstraZeneca India enter partnership in Type 2 diabetes<\/a><\/td>March 23, 2016<\/td>\n<\/tr>\n
Video Release - Digital launch of Pepmelt antacid campaign<\/a><\/td>March 11, 2016<\/td>\n<\/tr>\n
Note on Digital launch of Pepmelt antacid campaign<\/a><\/td>March 11, 2016<\/td>\n<\/tr>\n
Sun Pharma Consumer Healthcare Business enhances presence in digestive care<\/a><\/td>March 11, 2016<\/td>\n<\/tr>\n
Sun Pharma Global Consumer Healthcare signs Indian cricket captain MS Dhoni as Revital H brand ambassador<\/a><\/td>March 08, 2016<\/td>\n<\/tr>\n
FY16 Q3 Earnings Call Transcript<\/a><\/td>February 26, 2016<\/td>\n<\/tr>\n
FY16 Q3 Financial Press Release<\/a><\/td>February 12, 2016<\/td>\n<\/tr>\n
Sun Pharma launches Imatinib Mesylate in USA<\/a><\/td>February 01, 2016<\/td>\n<\/tr>\n
Sun Pharma to announce third quarter results on February 12, 2016<\/a><\/td>January 30, 2016<\/td>\n<\/tr>\n
Revital H announces association with Patna Pirates, Kabbadi Team as Official Health Partner<\/a><\/td>January 27, 2016<\/td>\n<\/tr>\n
Transcript - Update on Halol facility<\/a><\/td>January 04, 2016<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n\n\n\n\n\t\n\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t
Press Release<\/th>Date<\/th>\n<\/tr>\n<\/thead>\n
Sun Pharma receives Warning Letter for Halol facility<\/a><\/td>December 19, 2015<\/td>\n<\/tr>\n
Sun Pharma announces divestment of US manufacturing unit<\/a><\/td>December 14, 2015<\/td>\n<\/tr>\n
Sun Pharma announces research collaboration with Weizmann Institute of Science, Israel & Health Research Institute of Santiago, Spain for brain therapies<\/a><\/td>December 10, 2015<\/td>\n<\/tr>\n
Sun Pharma announces US FDA approval for generic Gleevec\u00ae<\/a><\/td>December 04, 2015<\/td>\n<\/tr>\n
Sun Pharma announces its association with World Champion Snowboarder Kelly Clark for Absorica\u00ae<\/a><\/td>December 02, 2015<\/td>\n<\/tr>\n
FY16 Q2 Earnings Call Transcript<\/a><\/td>November 27, 2015<\/td>\n<\/tr>\n
FY16 Q2 Financial Press Release<\/a><\/td>November 07, 2015<\/td>\n<\/tr>\n
Sun Pharma Successfully Acquires InSite Vision<\/a><\/td>November 03, 2015<\/td>\n<\/tr>\n
Volini announces Sania Mirza and Sunil Chhetri as brand ambassadors<\/a><\/td>November 03, 2015<\/td>\n<\/tr>\n
Sun Pharma completes tender offer for InSite Vision<\/a><\/td>October 28, 2015<\/td>\n<\/tr>\n
Sun Pharma Q2 & H1 FY16 financial results on November 07, 2015<\/a><\/td>October 26, 2015<\/td>\n<\/tr>\n
Sun Pharma announces Absorica patent litigation settlement<\/a><\/td>October 05, 2015<\/td>\n<\/tr>\n
Sun Pharma commences Tender Offer for Acquisition of InSite Vision<\/a><\/td>September 29, 2015<\/td>\n<\/tr>\n
Strides Arcolab acquires CNS divisions of erstwhile Ranbaxy<\/a><\/td>September 19, 2015<\/td>\n<\/tr>\n
Sun Pharma to acquire InSite Vision<\/a><\/td>September 15, 2015<\/td>\n<\/tr>\n
Sun Pharma announces successful completion of Opiates business acquisition in Australia<\/a><\/td>September 01, 2015<\/td>\n<\/tr>\n
FY16 Q1 Earnings Call Transcript<\/a><\/td>August 25, 2015<\/td>\n<\/tr>\n
Sun Pharma announces US FDA approval for Ximino<\/a><\/td>August 19, 2015<\/td>\n<\/tr>\n
FY16 Q1 Financial Press Release<\/a><\/td>August 11, 2015<\/td>\n<\/tr>\n
Sun Pharma to announce first quarter results on August 11, 2015<\/a><\/td>July 29, 2015<\/td>\n<\/tr>\n
Transcript - Sun Pharma Business Update<\/a><\/td>July 24, 2015<\/td>\n<\/tr>\n
Sun Pharma provides business update<\/a><\/td>July 20, 2015<\/td>\n<\/tr>\n
SPARC Licenses XelprosTM (Latanoprost BAK-free) to Sun Pharma<\/a><\/td>June 09, 2015<\/td>\n<\/tr>\n
Sun Pharma and AstraZeneca enter into distribution agreement for ticagrelor in India<\/a><\/td>June 02, 2015<\/td>\n<\/tr>\n
Sun Pharma to announce fourth quarter FY15 results on May 29, 2015<\/a><\/td>May 15, 2015<\/td>\n<\/tr>\n
Sun Pharma and the Technion form Research Collaboration to Develop New Class of Oncology Drugs<\/a><\/td>April 15, 2015<\/td>\n<\/tr>\n
Sun Pharma announces closure of merger deal with Ranbaxy<\/a><\/td>March 25, 2015<\/td>\n<\/tr>\n
Sun Pharma announces closure of merger deal with Ranbaxy- Profile of Sun Pharma<\/a><\/td>March 25, 2015<\/td>\n<\/tr>\n
Sun Pharma announces closure of merger deal with Ranbaxy- Investor Relations Presentation <\/a><\/td>March 25, 2015<\/td>\n<\/tr>\n
Sun Pharma announces closure of merger deal with Ranbaxy- Factsheet <\/a><\/td>March 25, 2015<\/td>\n<\/tr>\n
Sun Pharma announces closure of merger deal with Ranbaxy- Profile of Chairman & MD <\/a><\/td>March 25, 2015<\/td>\n<\/tr>\n
Sun Pharma announces closure of merger deal with Ranbaxy- Growing Together Film <\/a><\/td>March 25, 2015<\/td>\n<\/tr>\n
Press Conference Webcast: Sun Pharma - Ranbaxy Merger<\/a><\/td>March 25, 2015
\n<\/td>\n<\/tr>\n
Sun Pharma to buy GSK\u2019s Opiates business in Australia<\/a><\/td>March 03, 2015<\/td>\n<\/tr>\n
FY15 Q3 Earning Call Transcript<\/a><\/td>February 24, 2015<\/td>\n<\/tr>\n
Press Release SPIL Financials Q3 FY15<\/a><\/td>February 14, 2015
\n<\/td>\n<\/tr>\n
Sun Pharma to announce third quarter results on February 14, 2015<\/a><\/td>February 09, 2015<\/td>\n<\/tr>\n
Sun Pharma receives US FTC clearance for Ranbaxy acquisition<\/a><\/td>February 02, 2015<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n\n\n\n\n\t\n\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t
Press Release<\/th>Date<\/th>\n<\/tr>\n<\/thead>\n
CCI approves Ranbaxy acquisition by Sun Pharma<\/a><\/td>December 08, 2014<\/td>\n<\/tr>\n
Sun Pharma to announce second quarter results on November 13, 2014<\/a><\/td>October 30, 2014<\/td>\n<\/tr>\n
Sun Pharma and Merck & Co. Inc. Enter into Licensing Agreement for Tildrakizumab<\/a><\/td>September 17, 2014<\/td>\n<\/tr>\n
Form IV contained in Schedule II to the Combination Regulations under Sec 29(2) of Competition Act, 2002 (as amended)<\/a><\/td>September 04, 2014<\/td>\n<\/tr>\n
Q1 FY15 Earnings Call Transcript<\/a><\/td>August 23, 2014<\/td>\n<\/tr>\n
Q1 FY15 Financial Press Release<\/a><\/td>August 12, 2014<\/td>\n<\/tr>\n
Sun Pharma to announce first quarter results on August 12, 2014<\/a><\/td>July 30, 2014<\/td>\n<\/tr>\n
Sun Pharma acquires Pharmalucence<\/a><\/td>July 16, 2014<\/td>\n<\/tr>\n
Q4 FY14 Financial Press Release<\/a><\/td>May 29, 2014<\/td>\n<\/tr>\n
Sun Pharma to announce Q4 and FY14 results on May 29, 2014<\/a><\/td>May 16, 2014<\/td>\n<\/tr>\n
Sun Pharma announces settlement of litigation for generic Gleevec\u00ae in US<\/a><\/td>May 15, 2014<\/td>\n<\/tr>\n
Sun Pharma announces manufacturing consolidation<\/a><\/td>May 02, 2014<\/td>\n<\/tr>\n
Transcript Sun Pharma - Ranbaxy Merger Conference Call<\/a><\/td>April 16, 2014<\/td>\n<\/tr>\n
Clarification on Silverstreet Investment in Ranbaxy<\/a><\/td>April 09, 2014<\/td>\n<\/tr>\n
Investor Presentation: Sun Pharma & Ranbaxy merger<\/a><\/td>April 07, 2014<\/td>\n<\/tr>\n
Sun Pharma to acquire Ranbaxy in a US$ 4 billion landmark transaction<\/a><\/td>April 06, 2014<\/td>\n<\/tr>\n
Import Alert for Karkhadi unit from US FDA<\/a><\/td>March 13, 2014<\/td>\n<\/tr>\n
FY14 Q3 Earnings call transcript<\/a><\/td>February 25, 2014<\/td>\n<\/tr>\n
Rekha Sethi appointed as an additional independent director of Sun Pharma Board<\/a><\/td>February 13, 2014<\/td>\n<\/tr>\n
FY14 Q3 Financial Press Release<\/a><\/td>February 13, 2014<\/td>\n<\/tr>\n
Sun Pharma announces US FDA approval for generic Temodar\u00ae<\/a><\/td>February 13, 2014<\/td>\n<\/tr>\n
Sun Pharma to announce third quarter results on February 13, 2014<\/a><\/td>January 29, 2014<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n\n\n\n\n\t\n\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t
Press Release<\/th>Date<\/th>\n<\/tr>\n<\/thead>\n
Sun Pharma announces US FDA approval for generic Cymbalta\u00ae<\/a><\/td>December 12, 2013<\/td>\n<\/tr>\n
FY14 Q2 Earnings call transcript<\/a><\/td>November 22, 2013<\/td>\n<\/tr>\n
FY14 Q2 Financial Press Release<\/a><\/td>November 13, 2013<\/td>\n<\/tr>\n
Sun Pharma to announce second quarter results on November 13, 2013<\/a><\/td>October 28, 2013<\/td>\n<\/tr>\n
Sun Pharma and Intrexon Form Joint Venture to Develop New Class of Therapeutics for Ocular Diseases<\/a><\/td>October 01, 2013<\/td>\n<\/tr>\n
Sun Pharma announces USFDA approval for generic Prevacid\u00ae<\/a><\/td>September 14, 2013<\/td>\n<\/tr>\n
FY14 Q1 Financial Press Release<\/a><\/td>August 09, 2013<\/td>\n<\/tr>\n
Sun Pharma to announce first quarter results on August 09, 2013<\/a><\/td>July 23, 2013<\/td>\n<\/tr>\n
Sun Pharma announces USFDA approval for generic Prandin\u00ae<\/a><\/td>July 12, 2013<\/td>\n<\/tr>\n
Sun Pharma settles generic Protonix\u00ae litigation<\/a><\/td>June 12, 2013<\/td>\n<\/tr>\n
FY13 Q4 Earnings Call Transcript<\/a><\/td>June 12, 2013<\/td>\n<\/tr>\n
Sun Pharma announces USFDA approval for generic Depo\u00ae-Testosterone Injection<\/a><\/td>June 04, 2013<\/td>\n<\/tr>\n
Sun Pharma Announces 1:1 Bonus<\/a><\/td>May 28, 2013<\/td>\n<\/tr>\n
Sun Pharma reports strong performance<\/a><\/td>May 28, 2013<\/td>\n<\/tr>\n
Sun Pharma to announce Q4 and FY13 results on May 28, 2013<\/a><\/td>May 17, 2013<\/td>\n<\/tr>\n
Sun Pharma and Taro Announce Termination of Proposed Transaction<\/a><\/td>February 08, 2013<\/td>\n<\/tr>\n
Sun Pharma announces USFDA approval for generic Doxil\u00ae<\/a><\/td>February 05, 2013<\/td>\n<\/tr>\n
Sun Pharma to announce third quarter results on February 08, 2013<\/a><\/td>January 25, 2013<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n[table \u201c\u201d not found \/]
\n<\/p>\n","protected":false},"author":1,"featured_media":0,"parent":0,"menu_order":0,"comment_status":"closed","ping_status":"closed","template":"","meta":{"_et_pb_use_builder":"on","_et_pb_old_content":"","_et_gb_content_width":"","inline_featured_image":false,"_uf_show_specific_survey":0,"_uf_disable_surveys":false,"footnotes":""},"class_list":["post-42","page","type-page","status-publish","hentry"],"yoast_head":"\nMedia | Press Releases - Sun Pharmaceutical<\/title>\n<meta name=\"description\" content=\"Here you will find our latest & archived press releases and our corporate brand guidelines.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/dev.sunpharma.com\/he\/media\/\" \/>\n<meta property=\"og:locale\" content=\"he_IL\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Media | Press Releases - Sun Pharmaceutical\" \/>\n<meta property=\"og:description\" content=\"Here you will find our latest & archived press releases and our corporate brand guidelines.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/dev.sunpharma.com\/he\/media\/\" \/>\n<meta property=\"og:site_name\" content=\"Sun Pharmaceutical Industries Ltd.\" \/>\n<meta property=\"article:modified_time\" content=\"2026-01-22T17:58:07+00:00\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data1\" content=\"2 \u05d3\u05e7\u05d5\u05ea\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/dev.sunpharma.com\\\/media\\\/\",\"url\":\"https:\\\/\\\/dev.sunpharma.com\\\/media\\\/\",\"name\":\"Media | Press Releases - Sun Pharmaceutical\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/dev.sunpharma.com\\\/#website\"},\"datePublished\":\"2020-04-04T16:44:21+00:00\",\"dateModified\":\"2026-01-22T17:58:07+00:00\",\"description\":\"Here you will find our latest & archived press releases and our corporate brand guidelines.\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/dev.sunpharma.com\\\/media\\\/#breadcrumb\"},\"inLanguage\":\"he-IL\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/dev.sunpharma.com\\\/media\\\/\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/dev.sunpharma.com\\\/media\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/dev.sunpharma.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Media\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/dev.sunpharma.com\\\/#website\",\"url\":\"https:\\\/\\\/dev.sunpharma.com\\\/\",\"name\":\"Sun Pharmaceutical Industries Ltd.\",\"description\":\"\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/dev.sunpharma.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"he-IL\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Media | Press Releases - Sun Pharmaceutical","description":"Here you will find our latest & archived press releases and our corporate brand guidelines.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/dev.sunpharma.com\/he\/media\/","og_locale":"he_IL","og_type":"article","og_title":"Media | Press Releases - Sun Pharmaceutical","og_description":"Here you will find our latest & archived press releases and our corporate brand guidelines.","og_url":"https:\/\/dev.sunpharma.com\/he\/media\/","og_site_name":"Sun Pharmaceutical Industries Ltd.","article_modified_time":"2026-01-22T17:58:07+00:00","twitter_card":"summary_large_image","twitter_misc":{"Est. reading time":"2 \u05d3\u05e7\u05d5\u05ea"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"WebPage","@id":"https:\/\/dev.sunpharma.com\/media\/","url":"https:\/\/dev.sunpharma.com\/media\/","name":"Media | Press Releases - Sun Pharmaceutical","isPartOf":{"@id":"https:\/\/dev.sunpharma.com\/#website"},"datePublished":"2020-04-04T16:44:21+00:00","dateModified":"2026-01-22T17:58:07+00:00","description":"Here you will find our latest & archived press releases and our corporate brand guidelines.","breadcrumb":{"@id":"https:\/\/dev.sunpharma.com\/media\/#breadcrumb"},"inLanguage":"he-IL","potentialAction":[{"@type":"ReadAction","target":["https:\/\/dev.sunpharma.com\/media\/"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/dev.sunpharma.com\/media\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/dev.sunpharma.com\/"},{"@type":"ListItem","position":2,"name":"Media"}]},{"@type":"WebSite","@id":"https:\/\/dev.sunpharma.com\/#website","url":"https:\/\/dev.sunpharma.com\/","name":"Sun Pharmaceutical Industries Ltd.","description":"","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/dev.sunpharma.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"he-IL"}]}},"_links":{"self":[{"href":"https:\/\/dev.sunpharma.com\/he\/wp-json\/wp\/v2\/pages\/42","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/dev.sunpharma.com\/he\/wp-json\/wp\/v2\/pages"}],"about":[{"href":"https:\/\/dev.sunpharma.com\/he\/wp-json\/wp\/v2\/types\/page"}],"author":[{"embeddable":true,"href":"https:\/\/dev.sunpharma.com\/he\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/dev.sunpharma.com\/he\/wp-json\/wp\/v2\/comments?post=42"}],"version-history":[{"count":111,"href":"https:\/\/dev.sunpharma.com\/he\/wp-json\/wp\/v2\/pages\/42\/revisions"}],"predecessor-version":[{"id":18362,"href":"https:\/\/dev.sunpharma.com\/he\/wp-json\/wp\/v2\/pages\/42\/revisions\/18362"}],"wp:attachment":[{"href":"https:\/\/dev.sunpharma.com\/he\/wp-json\/wp\/v2\/media?parent=42"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}